cytarabine has been researched along with Dysmyelopoietic Syndromes in 454 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 82 (18.06) | 18.7374 |
| 1990's | 142 (31.28) | 18.2507 |
| 2000's | 89 (19.60) | 29.6817 |
| 2010's | 105 (23.13) | 24.3611 |
| 2020's | 36 (7.93) | 2.80 |
| Authors | Studies |
|---|---|
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Guo, Z; Liu, L; Liu, P; Ren, X; Wang, F; Xu, W; Xu, Y; Zhang, H; Zhang, S; Zheng, L | 1 |
| Shimony, S; Stahl, M; Stone, RM | 1 |
| Assis-Mendonça, GR; Bueno, MLP; da Silva, JAF; Duarte, ASS; Ferro, KP; Pericole, FV; Rego, EM; Roversi, FM; Saad, STO; Shiraishi, RN; Torello, CO | 1 |
| Ahmed, SO; Aljurf, M; Alotaibi, S; Mohty, M; Niederwieser, D; Sanz, J | 1 |
| Biemond, BJ; Boersma, RS; Chalandon, Y; de Weerdt, O; Deeren, D; Efthymiou, A; Fehr, M; Graux, C; Gregor, M; Heim, D; Janssen, JJWM; Jongen-Lavrencic, M; Klein, SK; Legdeur, MCJC; Löwenberg, B; Manz, M; Ossenkoppele, GJ; Pabst, T; Sinnige, HAM; Spertini, O; Stüssi, G; Tick, LW; van der Poel, MWM; van Norden, Y; van Obbergh, F; van Sluis, G; Westerweel, PE | 1 |
| Beeler-Marfisi, J; Bienzle, D; Calvalido, J; Matsuyama, A; Mutsaers, AJ; Richardson, D; Wood, RD | 1 |
| Chang, K; Guan, F; Li, H; Li, X; Lu, Y; Xie, C | 1 |
| Bo, J; Dou, L; Gao, C; Gao, X; Li, H; Liu, D; Lu, N; Wang, L; Wei, Y; Wu, Y; Zhang, R; Zhu, C | 1 |
| Arnold, C; Batten, LM; Betteridge, S; Canham, J; Cavenagh, J; Dennis, M; Dillon, R; Freeman, SD; Gilkes, A; Hemmaway, C; Hinson, EL; Kleeman, M; Knapper, S; Kottaridis, P; Mehta, P; Othman, J; Overgaard, UM; Potter, N; Russell, NH; Villiers, W; Wilhelm-Benartzi, C; Wych, J | 1 |
| de Witte, T; Muus, P | 1 |
| Bonmati, C; Campidelli, A; D'Aveni-Piney, M; Divoux, M; Kicki, C; Notarantonio, AB; Pagliuca, S; Roth-Guépin, G; Rubio, MT | 1 |
| Fenaux, P; Peterlin, P | 1 |
| Sasaki, K | 1 |
| Adès, L; Fenaux, P; Sébert, M | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Alfayez, M; Daver, N; Kadia, T; Kantarjian, H; Ravandi-Kashani, F | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Tao, Y; Wu, D; Wu, L; Xiu, C; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Goldsmith, SR; Lovell, AR; Schroeder, MA | 1 |
| Alonso Domínguez, JM; Arquero, T; Atance, M; Chamizo, C; Piris, MA; Prieto-Torres, L; Requena, L; Rodriguez-Pinilla, SM; Salgado, RN; Soto, C | 1 |
| A von dem Borne, P; Bargetzi, M; Biemond, BJ; Breems, DA; Chalandon, Y; Cloos, J; de Jongh, E; de Weerdt, O; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, JJJW; Jaspers, A; Jongen-Lavrencic, M; Klein, SK; Löwenberg, B; Maertens, J; Manz, M; Michaux, L; Ossenkoppele, GJ; Pabst, T; Stuessi, G; Tick, L; Valk, P; van der Klift, M; van der Poel, MWM; van der Velden, WJFM; van Marwijk Kooy, M; van Norden, Y; van Rhenen, A; Vekemans, MC | 1 |
| Borthakur, G; Bueso-Ramos, C; Class, CA; Cortes, JE; Daver, N; DiNardo, CD; Do, KA; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Khoury, JD; Konopleva, M; Montalban-Bravo, G; Naqvi, K; Patel, K; Pierce, S; Ravandi, F; Routbort, M; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Beachamp, Z; Bossé, R; Brown, R; Cline, C; Cogle, CR; Collins, B; Hawkins, KE; Hiemenz, J; Hsu, J; May, WS; Moreb, JS; Norkin, M; Pettiford, LC; Turner, D; Uckun, F; Wingard, JR; Wise, E | 1 |
| Benmachiche, M; Guex-Crosier, Y; Häller, CNI; Sadeghi, Y | 1 |
| Li, TT; Ran, XH; Sun, L; Wang, LJ; Wu, XF | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Bhatnagar, B; Koenig, KL; Sahasrabudhe, KD; Sigmund, AM | 1 |
| Chien, KS; Garcia-Manero, G; Montalban-Bravo, G | 1 |
| Arber, DA; Erba, HP | 1 |
| Cafaro, A; Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Martinelli, G; Masini, C; Silimbani, P; Simonetti, G | 1 |
| Chacim, S; Mariz, JM; Tavares, M | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Chiang, T; Miller, C; Seabury, R; Triesel, K | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Chang, C; Fang, Y; Guo, J; Jia, Y; Shi, L; Wu, D; Wu, L; Zhang, Z; Zhao, Y | 1 |
| Cortes, JE; Faderl, S; Hogge, DE; Kolitz, JE; Lancet, JE; Lin, TL; Rizzieri, DA; Ryan, DH; Ryan, RJ; Schiller, GJ; Solomon, SR; Uy, GL; Wieduwilt, MJ | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Guerra, V; Jabbour, EJ; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Levis, M; Ohanian, M; Pemmaraju, N; Pierce, S; Pinsoy, MR; Ravandi, F; Swaminathan, M; Wierda, WG; Xiao, L | 1 |
| An, L; Chu, X; Li, L; Liu, Y; Wang, J; Wang, L; Xu, J | 1 |
| Emadi, A; Faderl, S; Finn, L; Garcia, R; Jacoby, MA; Male, HJ; Powell, BL; Saba, NS; Seiter, K | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Heisel, RW; Lim, SH; Mascara, GP; Oleksiuk, LM; Sutton, RR; Weber, DR; Winger, DG | 1 |
| Alonzo, TA; Berman, JN; Campana, D; Coustan-Smith, E; Gamis, AS; Ge, Y; Gerbing, RB; Head, D; Hirsch, B; Hitzler, JK; Lacayo, NJ; Mast, K; Mathew, P; Raimondi, S; Sorrell, AD; Taub, JW; Wang, YC | 1 |
| Absalon, MJ; Ahmed, A; August, K; Baker, SD; Boklan, J; Brown, PA; Cooper, TM; Gore, L; Li, L; Macy, ME; Magoon, D; Narendran, A; Pollard, J; Sison, EAR; Trippett, T | 1 |
| Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P | 1 |
| Bornhäuser, M; Böttner, A; Dührsen, U; Ehninger, G; Helas, S; Herbst, R; Herold, S; Hindahl, H; Kullmer, J; Mies, A; Mohr, B; Oelschlägel, U; Platzbecker, U; Röllig, C; Sauer, M; Sayehli, C; Sockel, K; Thiede, C | 1 |
| Blijlevens, NMA; Kox, M; Leijte, GP; Pickkers, PP; Scheffer, GJ; Timmermans, K | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Al-Ali, HK; Beach, CL; Butrym, A; Candoni, A; Cavenagh, J; Del Castillo, TB; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Minden, MD; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Weaver, J; Wierzbowska, A | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Kim, M; Williams, S | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Pollyea, DA; Sharma, P | 1 |
| Adès, L; Almeida, A; Ball, B; Cluzeau, T; DeZern, AE; Fenaux, P; Germing, U; Gore, SD; Komrokji, RS; Platzbecker, U; Pleyer, L; Prebet, T; Sekeres, MA; Vey, N | 1 |
| Azam, M; Bu, J; Ding, W; Hu, C; Huang, G; Jin, J; Kesarwani, M; Lin, P; Luo, Y; Ma, L; Mei, C; Ren, Y; Tang, Y; Tong, H; Xu, W; Yan, X; Ye, L; Zhan, D; Zhang, H; Zhou, X; Zhou, Y; Zhu, S | 1 |
| Appelbaum, FR; Erba, HP; Estey, E; Garcia-Manero, G; Nand, S; Othus, M; Sekeres, MA | 1 |
| Hale, G; Kussman, A; Oshrine, B; Petrovic, A; Shyr, D | 1 |
| Chan, G; Cortes, JE; DesJardins, P; Fiedler, W; Heidel, FH; Hellmann, A; Heuser, M; Laird, AD; Ma, WW; Montesinos, P; O'Connell, A; Ottmann, O; Pollyea, DA; Robak, T; Shaik, MN; Smith, BD; Zeremski, M | 1 |
| Hoy, SM | 1 |
| Guo, X; Zhang, X | 1 |
| Cao, YP; Li, JG; Zhang, JL | 1 |
| Ali, S; Bowen, D; Burnett, AK; Hills, RK; Hunter, AE; Knapper, S; McMullin, MF; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Alves, V; Barbosa-Ribeiro, A; Gonçalves, AC; Sarmento-Ribeiro, AB; Silva, T | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Sekeres, MA | 1 |
| Asano, S; Ebihara, Y; Jo, N; Kato, S; Kawamata, T; Konuma, T; Mochizuki, S; Ohno, N; Oiwa-Monna, M; Ooi, J; Takahashi, S; Tojo, A; Uchimaru, K; Yokoyama, K; Yuji, K | 1 |
| Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB | 1 |
| Bryan, J; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Brandt, M; Choi, S; Cortes, J; Faderl, S; Garcia-Manero, G; Ghanem, H; Huang, X; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Tohyama, K | 1 |
| Adès, L; Santini, V | 1 |
| Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R | 1 |
| Boyano-Adánez, Mdel C; Bueso-Ramos, C; Calin, G; Gañán-Gómez, I; García-Manero, G; Pierce, S; Wei, Y; Yang, H | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Cui, GX; Wu, WZ; Zhang, YP | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Fukano, R; Inagaki, J; Kurauchi, K; Noguchi, M; Okamura, J; Tanioka, S | 1 |
| Abkowitz, JL; Appelbaum, FR; Becker, PS; Estey, EH; Forman, SJ; Gardner, KM; Hendrie, PC; Medeiros, BC; Othus, M; Pagel, JM; Parks, C; Scott, BL; Stein, AS; Walter, RB; Wood, BL | 1 |
| Becker, PS; Chen, TL; Dean, C; Estey, EH; Hendrie, PC; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB | 1 |
| Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
| Becker, PS; Buckley, SA; Dean, C; Estey, EH; Gooley, TA; Hendrie, P; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Smith, K; Walter, RB; Wood, BL | 1 |
| Björkholm, M; Blennow, O; Cederlund, K; Dahlén, T; Kalin, M; Ljungman, P; Nordlander, A | 1 |
| Asano, S; Ishii, H; Kato, S; Konuma, T; Oiwa-Monna, M; Takahashi, S; Tojo, A | 1 |
| Kakiuchi, S; Kawamoto, S; Matsuoka, H; Minami, H; Yakushijin, K; Yamamoto, K | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Aoki, K; Aotsuka, N; Arai, Y; Atsuta, Y; Kato, K; Kondo, T; Kouzai, Y; Nakamae, H; Nakaseko, C; Onishi, Y; Ota, S; Ozawa, Y; Takahashi, S; Takami, A; Takeda, J; Yamaguchi, H | 1 |
| Chi, J; Costeas, P; Liu, L; Nian, Q; Wang, L; Wei, C; Xiao, Q; Yang, Z | 1 |
| Kuang, X; Nian, Q; Wang, L; Wang, X; Wei, C; Zhang, Z | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Chang, C; Chao, X; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Amadori, S; Baron, F; Bron, D; de Witte, T; Halkes, C; Meert, L; Muus, P; Selleslag, D; Suciu, S; Willemze, R | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Cabanillas, F; Cheah, CY; Chihara, D; Fayad, LE; Goy, A; Hagemeister, FB; Kantarjian, H; Kwak, LW; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, ML; Westin, JR; Younes, A | 1 |
| Brennig, S; Buchegger, T; Hetzel, M; Lachmann, N; Moritz, T; Schambach, A | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Baumann, FT; Bloch, W; Elter, T; Garthe, A; Hallek, M; Hartig, P; Joisten, N; Oberste, M; Schenk, A; Wolf, F; Zimmer, P | 1 |
| Liu, ZW; Wang, DZ; Yang, XF; Zhu, YN | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Wang, FX; Wang, JL; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Jiang, Q; Li, L; Sun, J; Xie, M; Xie, W; Yang, X; Ye, X; Zheng, Y; Zhu, J; Zhu, L; Zhu, M | 1 |
| Bohannan, Z; Borthakur, G; Bueso-Ramos, C; Daver, N; Faderl, S; Garcia-Manero, G; Hosing, C; Jabbour, E; Kadia, T; Kantarjian, HM; Khoury, JD; Maduike, R; Miller, D; Patel, K; Pemmaraju, N; Ravandi, F; Sasaki, K; Verstovsek, S | 1 |
| Amadori, S; Baron, F; de Witte, T; Halkes, CJ; Marie, JP; Meert, L; Meloni, G; Muus, P; Pruijt, H; Ramadan, SM; Selleslag, D; Suciu, S; Venditti, A; Vignetti, M; Willemze, R; Wittnebel, S | 1 |
| de Melo Campos, P; Favaro, P; Lopes, MR; Machado-Neto, JA; Pereira, JK; Saad, ST; Traina, F | 1 |
| Finn, LE; Foran, JM; Hess, AD; Karp, JE; Kaufmann, SH; Knorr, KL; Smith, BD | 1 |
| Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Thomas, DA; Verstovsek, S | 1 |
| Gopaluni, S; Husain, J; Rajan, A; Shah, C; Shah, H | 1 |
| Cao, XM; Chen, YX; He, AL; Liu, J; Ma, XR; Zhang, WG | 1 |
| Abboud, CN; Augustin, K; Cashen, A; DiPersio, JF; Luo, J; Martin, MG; Procknow, E; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P | 1 |
| Gattermann, N; Germing, U; Giagounidis, A; Haas, R; Kobbe, G; Kündgen, A; Nachtkamp, K; Strupp, C | 1 |
| Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S | 1 |
| Santini, V | 1 |
| Burnett, AK; Dennis, M; Goldstone, A; Hills, RK; McMullin, MF; Milligan, D; Pallis, M; Prentice, A; Russell, N; Sellwood, E; Wheatley, K | 1 |
| Chang, H; He, C; Liu, T; Xiang, B; Xu, CG; Xu, J | 1 |
| Chang, CK; He, Q; Li, X; Song, LQ; Su, JY; Wu, LY; Xu, L; Zhang, X; Zhou, LY | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Song, L; Su, J; Wu, L; Xu, L; Zhang, X | 1 |
| Berry, D; Borthakur, G; Faderl, S; Ferrajoli, A; Huang, X; Issa, JP; Kantarjian, H; Morris, G; Ravandi, F; Torma, R | 1 |
| Imanishi, D; Imoto, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Miyazaki, Y; Morita, Y; Naoe, T; Ohnishi, K; Ohno, R; Tanimoto, M; Yagasaki, F | 1 |
| Backstrom, J; Beach, CL; Beyne-Rauzy, O; Duehrsen, U; Fenaux, P; Gattermann, N; Gore, SD; Hellström-Lindberg, E; List, A; McKenzie, D; Mufti, GJ; Ramos, F; Seymour, JF | 1 |
| Jin, J; Qian, WB; Xu, WL | 1 |
| Chen, S; He, Y; Zhu, Y | 1 |
| Bourke, B; Cortelazzo, S; Piccin, A; Rovigatti, U; Smith, OP | 1 |
| Abidi, M; Abrams, J; Atallah, E; Ayash, L; Bentley, G; Ratanatharathorn, V; Uberti, J | 1 |
| Bae, JY; Kim, BK; Kim, HK; Kim, I; Koh, Y; Lee, DS; Park, MH; Park, S; Park, SS; Song, EY; Yoon, SS | 1 |
| Karaman, R | 1 |
| Allen-Bard, S; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Segovia, J | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wright, JJ | 1 |
| Criscuolo, C; Ferrara, F; Izzo, T; Palmieri, S; Riccardi, C | 1 |
| Allen, SL; Asatiani, E; Feldman, EJ; Kolitz, JE; Lancet, JE; List, AF; Louie, AC; Mayer, LD; Ritchie, EK; Roboz, GJ; Swenson, C | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Chang, C; He, Q; Li, X; Pu, Q; Su, J; Wu, L; Zhang, X | 1 |
| Beutel, G; Buchholz, S; Dammann, E; Eder, M; Ganser, A; Krauter, J; Stadler, M; Trummer, A | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Cai, Z; Chiao, JW; Huang, H; Liu, D; Ni, W; Wei, G | 1 |
| Feldman, EJ | 1 |
| Endo, Y; Iwanaga, T; Miura, N; Miyoshi, N; Momoi, Y | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Kawabata, H; Kawanami, T; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Okazaki, T; Sakai, T; Satoh, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Y; Zhang, Z | 1 |
| Chen, BA; Chen, ZC; Fang, MY; He, GS; Jin, J; Liu, H; Liu, T; Ma, J; Qian, SX; Ruan, CG; Shao, ZH; Shen, ZX; Sun, AN; Wang, SY; Wu, DP; Xiao, ZJ; Xu, LP; Xu, XP | 1 |
| Ritchie, EK | 1 |
| Creutzig, U; Reinhardt, D; Sander, A; Von Neuhoff, C | 1 |
| Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J | 1 |
| Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W | 1 |
| Anderson, D; Greaves, P; Gribben, JG; Lillington, D; Lister, TA; Matthews, J; Montoto, S | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Bowen, DT; Durairaj, S; Groves, MJ; Hyslop, A; Keenan, N; Tauro, S | 1 |
| Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ | 1 |
| Andreu, R; Benlloch, L; Cervera, J; de la Rubia, J; García, I; Jarque, I; Jiménez, C; Martín, G; Martínez, J; Mollá, S; Moscardó, F; Regadera, A; Sanz, G; Sanz, M | 1 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P | 1 |
| Aivado, M; Germing, U; Haas, R; Kobbe, G; Körfer, R; Pape, H; Schneider, P; Schubert, D; Storb, R; Strupp, C; Tenderich, G; Zohren, F | 1 |
| Arai, H; Arai, Y; Gunji, H; Handa, T; Maki, K; Mitani, K; Nakamura, F; Nakamura, Y; Saito, K; Tadokoro, J | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Dansako, H; Fujii, N; Fujita, S; Kaneda, K; Kojima, K; Shinagawa, K; Tanimoto, M; Yano, T; Yasukawa, M; Yoshida, C | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Bacigalupo, A; Balleari, E; Ballerini, F; Beltrami, G; Canepa, L; Carella, AM; Carrara, P; Cerri, R; Clavio, M; Galbusera, V; Gatto, S; Ghio, R; Gobbi, M; Miglino, M; Pierri, I; Quintino, S; Risso, M; Sessarego, M; Varaldo, R; Venturino, C | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Amadori, S; Anak, O; Aul, C; Beeldens, F; Belhabri, A; de Witte, T; Ferrant, A; Hess, U; Jehn, U; Labar, B; Mandelli, F; Muus, P; Oosterveld, M; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| Ishigatsubo, Y; Kanamori, H; Sakai, R; Takabayashi, M | 1 |
| Bordessoule, D; Chevret, S; Chomienne, C; Degos, L; Desablens, B; Fenaux, P; Ferrant, A; Fey, M; Lobe, I; Mounier, C; Rigal-Huguet, F; Sanz, M; Vekhoff, A | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Bernell, P; Björkholm, M; Celsing, F; Dahl, IM; Dybedal, I; Gahrton, G; Hast, R; Hellström-Lindberg, E; Lerner, R; Lindberg, G; Linder, O; Löfvenberg, E; Nilsson-Ehle, H; Oberg, G; Ohm, L; Paul, C; Samuelsson, J; Tangen, JM; Tidefelt, U; Turesson, I; Wahlin, A; Wallvik, J; Winquist, I | 1 |
| Hoffbrand, AV; Koh, M; Mehta, A; Potter, M; Prentice, HG; Rankin, P; Virchis, A | 1 |
| Chang, YW; Cho, HC; Cho, HI; Hur, M; Kim, SH; Kim, YR; Lee, KM; Park, YI | 1 |
| Advani, R; Bennett, JM; Chin, DL; Dewald, G; Dugan, K; Greenberg, PL; Lee, SJ; Letendre, L; Lum, B; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS | 1 |
| Biesma, DH; Daenen, SM; Delforge, M; Graveland, WJ; Löwenberg, B; Muus, P; Noordhuis, P; Ossenkoppele, GJ; Peters, GJ; Schaafsma, MR; Selleslag, D; Sonneveld, P; van der Holt, B; Verdonck, LF; Verhoef, GE; Westveer, PH | 1 |
| Bolaños-Meade, J; Gojo, I; Guo, C; Karp, JE | 1 |
| Boccadoro, M; Campa, E; Campana, S; Dellacasa, C; Ferrero, D; Foli, C | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Diehl, V; Hoffmann, M; Seiberlich, B; Staib, P; Tesch, H; Weihrauch, MR | 1 |
| Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E | 1 |
| Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M | 1 |
| Isidori, A; Malagola, M; Piccaluga, PP; Visani, G | 1 |
| Burnett, AK; Milligan, DW; Wheatley, K | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Cooper, T; Gandhi, V; Kantarjian, H; Plunkett, W | 1 |
| Alymara, V; Bourantas, KL; Chaidos, A; Tsiara, S; Tzouvara, E; Vartholomatos, G | 1 |
| Brandwein, J; Chun, K; Gupta, V; Minden, M; Schuh, A; Wells, R; Yi, QL | 1 |
| Albitar, M; Cortes, JE; Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Kornblau, S; Mattiuzzi, GN; O'Brien, SM; Thomas, D; Tsimberidou, AM; Verstovsek, S; Wierda, W | 1 |
| Kawauchi, K; Ogasawara, T; Yasuyama, M | 1 |
| Chan, GW; Miller, KB; Winer, ES | 1 |
| Califano, C; D'Arco, AM; Danise, P; De Simone, M; Ferrara, F; Mele, G; Palmieri, S; Pocali, B | 1 |
| Dick, JE; Khoury, H; Meng, YS; Minden, MD | 1 |
| Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP | 1 |
| Kolb, HJ; Ledderose, G; Schleuning, M; Schmid, C; Tischer, J | 1 |
| Amadori, S; Beksac, M; Cermak, J; de Witte, T; Fenaux, P; Harousseau, J; Loeffler-Ragg, J; Neuwirtova, R; Nuessler, V; Solbu, G; Suciu, S; Willemze, R; Zwierzina, H | 1 |
| Bonaccorso, R; Citarrella, P; Ciulla, A; Di Marco, P; Di Salvo, V; Gebbia, V; Mansueto, S; Tambone Reyes, M; Tinnirello, D | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Andreeff, M; Cahill, A; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Jeha, S; King, I; O'brien, SM; Sznol, M; Thomas, D; Verstovsek, S; Wierda, W; Yee, KW | 1 |
| Hattori, K; Hirai, H; Hosono, M; Sasaki, Y; Shibata, T; Suehiro, S | 1 |
| Aisa, Y; Arai, M; Enoki, S; Ikeda, Y; Mori, T; Nakazato, T; Okamoto, S; Yamazaki, R | 1 |
| Aul, C; Balleisen, L; Berdel, WE; Büchner, T; Eimermacher, H; Haferlach, T; Heinecke, A; Hiddemann, W; Kern, W; Kienast, J; Lengfelder, E; Ludwig, WD; Reichle, A; Sauerland, MC; Schnittger, S; Schoch, C; Serve, HL; Staib, P; Tchinda, J; Wörmann, B | 1 |
| Baer, MR; Barcos, M; Finlay, E; Pawarode, A; Sait, SN | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Aisa, Y; Ikeda, Y; Kato, J; Mihara, A; Mori, T; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Watanabe, R; Yamazaki, R; Yokoyama, A | 1 |
| Aulitzky, W; Cortes, J; Döhner, H; Fischer, T; Heidel, F; Huber, C; Kantarjian, H; Kindler, T; Letvak, L; Rücker, FG | 1 |
| Burnett, AK; Goldstone, AH; Hills, RK; McMullin, MF; Milligan, D; Prentice, AG; Wheatley, K | 1 |
| Aoki, Y; Ishida, Y; Ito, S; Murai, K; Onodera, S; Oyake, T; Sugawara, T; Suzuki, K; Tsukushi, Y; Uchiyama, T | 1 |
| Ishitani, K; Kida, M; Koike, K; Kuroda, H; Matsunaga, T; Neda, H; Niitsu, Y; Nobuoka, A; Sakamaki, S; Terui, T; Watanabe, H | 1 |
| Arana-Yi, C; Baer, MR; Barcos, M; Block, AW; Ford, LA; Sait, SN | 1 |
| Aisa, Y; Ikeda, Y; Ito, C; Kato, J; Kobayashi, N; Kondo, S; Kubo, A; Kurotori-Sotome, T; Mori, T; Ogawa, Y; Okamoto, S; Shigematsu, N; Tsubota, K; Watanabe, M; Yamada, K; Yashima, T | 1 |
| Dardenne, M; de Witte, T; Fenaux, P; Hayat, M; Jaksic, B; Peetermans, M; Selleslag, D; Strijckmans, P; Suciu, S; Zittoun, R | 1 |
| Geller, RB; Hillyer, CD; Schultz, AB | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Pierce, S; Robertson, L | 1 |
| Andreeff, M; Beran, M; Escudier, S; Estey, E; Kantarjian, H; Koller, C; Kornblau, S; O'Brien, S; Robertson, LE; Thall, P | 1 |
| Cosson, A; Fenaux, P; Lai, JL; Lepelley, P; Preudhomme, C; Soenen, V | 1 |
| Hiyoshi, M; Im, T; Mugitani, A; Park, K; Tatsumi, N; Yamane, T | 1 |
| Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F | 1 |
| Arie, Y; Hirai, M; Kikukawa, M; Kodo, H; Kumakawa, T; Mizutani, R; Mori, M; Murai, Y; Nakamura, N; Tsutsumi, H | 1 |
| Estey, E; Freireich, EJ; Kantarjian, H; Keating, M; Marlton, P; O'Brien, S; Pierce, S | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Heimpel, H; Heit, W; Huber, C; Kolbe, K; Maschmeyer, G; Mitrou, PS | 1 |
| Hino, K; Nakamaki, T | 1 |
| Buccisano, F; del Poeta, G; Favalli, C; Garaci, E; Grelli, S; Mastino, A; Papa, G; Scimò, MT; Stasi, R; Venditti, A | 1 |
| Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R | 1 |
| Ohno, R | 1 |
| Hotta, T; Ichikawa, A; Ito, T; Kagami, Y; Ohashi, H; Saito, H | 1 |
| Attal, M; Brousset, P; Dastugue, N; Demur, C; Duchayne, E; Rigal-Huguet, F; Robert, A; Rubie, H | 1 |
| Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP | 1 |
| Bernell, P; Hast, R; Kimby, E | 1 |
| Jack, FR; Summerfield, GP | 1 |
| Arbona, C; Benet, I; Carbonell, F; Escrig, V; García Conde, J; García Marco, J; Miguel García, A; Miguel Sosa, A; Navarro, I; Ruiz, A | 1 |
| Gardner, FH; Jodhani, M; Juneja, HS; Schottstedt, M; Trevarthen, D | 1 |
| Fukushima, T; Kuriyama, K; Miyazaki, Y; Moriuti, Y; Nagai, K; Tomonaga, M; Yoshida, S | 1 |
| Arakawa, M; Chou, T; Hayashi, N; Ishizuka, Y; Ito, S; Ogawa, O; Saeki, T; Tsukada, H; Wakabayashi, M | 1 |
| Forsblom, AM; Gahrton, G; Hellström-Lindberg, E; Kock, Y; Lindberg, G; Ost, A; Robèrt, KH | 2 |
| Chan, LC; Cheng, PN; Wan, TS; Wei, DC | 1 |
| He, HT; Wang, XT | 1 |
| Dardenne, M; de Witte, T; Delmer, A; Gerhartz, HH; Jacobs, A; Marcus, R; Solbu, G; Suciu, S; Visani, G; Zwierzina, H | 1 |
| Estey, EH; Kantarjian, H; Keating, M | 1 |
| Akashi, K; Gondo, H; Harada, M; Hayashi, S; Murakawa, M; Niho, Y; Okamura, T; Shibuya, T; Tamura, K; Teshima, T | 1 |
| Höffken, K; Hofmann, WK; Stauch, M | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Brianzoni, F; Centurioni, R; Ciniero, L; Danieli, G; Leoni, P; Montillo, M; Offidani, M; Olivieri, A; Salvi, A; Ziarati, H | 1 |
| Kobayashi, Y; Kondo, M; Maruo, N; Ozawa, M | 1 |
| Fujita, H; Hirayama, M; Kohgo, Y; Kura, T; Mogi, Y; Nakaya, R; Niitsu, Y; Tsuji, N; Watanabe, N | 1 |
| Baldicchi, L; Corneo, GM; Mangiagalli, M; Miccolis, IR; Pioltelli, P; Pogliani, EM | 1 |
| Buck, SA; Gurney, JG; Matherly, LH; Ravindranath, Y; Stout, ML; Taub, JW | 1 |
| Anderlini, P; Estey, EH; Kantarjian, HM; Keating, MJ; Luna, M; O'Brien, S; Pierce, S | 1 |
| Larson, RA | 1 |
| Nakamura, T; Ueda, T; Yamauchi, T | 1 |
| Cetin, M; Güler, E; Hiçsönmez, G; Mufti, GJ; Ozbek, N; Sayli, T; Tuncer, AM | 1 |
| Constantinidou, M; Dervenoulas, J; Economopoulos, T; Kostourou, A; Papageorgiou, E; Parharidou, A; Raptis, S; Stathakis, N | 1 |
| Dardenne, M; Fenaux, P; Gerhartz, HH; Hayat, M; Hoffbrand, AV; Jacobs, A; Solbu, G; Suciu, S; Walther, J; Zwierzina, HH | 1 |
| Ishida, Y; Ito, T; Kuriya, S; Miyairi, Y; Murai, K; Narigasawa, Y; Shimosegawa, K; Utsugisawa, T | 1 |
| Clausen, N; Hasle, H; Jacobsen, BB; Jacobsen, N; Kerndrup, G; Ostergaard, E; Yssing, M | 1 |
| Jensen, IM | 1 |
| Ganser, A; Hoelzer, D | 2 |
| Dan, K; Ogata, K; Yamada, T | 1 |
| Harada, M; Mizuno, S; Nagafuji, H; Shibuya, T | 1 |
| Hagiwara, S; Miwa, A; Nagai, M; Soda, Y; Takaku, F; Takezako, N; Togawa, A; Yuo, A | 1 |
| Munshi, NC; Tricot, GJ | 1 |
| Elonen, E; Hänninen, A; Järventie, G; Kätkä, K; Koistinen, P; Koivunen, E; Nousiainen, T; Oksanen, K; Pelliniemi, TT; Remes, K; Ruutu, T; Timonen, T; Volin, L | 1 |
| Akamatsu, M; Ikuno, Y; Nagatoshi, Y; Okamura, J; Tasaka, H | 1 |
| Burnett, AK; Goldstone, AH; Gray, RG; Hann, IM; Rees, JK; Stevens, RF; Wheatley, K | 1 |
| Duell, T; Gerhartz, HH; Mittermüller, J; Poleck, B; Schmetzer, HM; Wilmanns, W | 1 |
| Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
| Ganser, A; Geissler, RG; Schulte, P | 1 |
| Aul, C; Balleisen, L; Bennett, J; Büchner, T; Hiddemann, W; Hinrichs, H; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B | 1 |
| Abromowitch, M; Bayever, E; Coccia, PF; Gordon, BG; Harper, JL; Strandjord, SE; Warkentin, PI | 1 |
| Haase, D; Hiddemann, W; Schoch, C; Verbeek, W; Wörmann, B | 1 |
| Advani, SH; Gopal, R; Nair, CN; Nair, R; Saikia, TK; Soman, CS | 1 |
| Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J | 1 |
| Goldstone, AH; Harvey, D; Johnson, S; Nokes, TJ | 1 |
| Arning, M; Burk, M; Fartash, K; Heyll, A; Schneider, W; Volmer, M | 1 |
| Cullis, JO; Czepulkowski, B; Gover, PA; Grace, R; Mijovic, A; Mufti, GJ; Pagliuca, A; Parker, JE; Rassam, SM; Samaratunga, IR | 1 |
| Ganser, A; Karthaus, M | 1 |
| Amemiya, Y; Furukawa, Y; Hoshino, M; Imagawa, S; Izumi, T; Kawano, C; Kirito, K; Komatsu, N; Kuribara, R; Miura, Y; Miyazato, A; Muroi, K; Omine, K; Otsuki, T; Shimizu, R; Suzuki, T; Tabata, M; Takahashi, H; Takatoku, M; Terui, Y; Tomizuka, H; Toshima, M; Tsunoda, J; Uchida, M; Yoshida, M | 1 |
| Amian, A; Cañavate, M; Diéguez, JC; Fernández-Jurado, A; Martino, ML; Moreno, MV; Polo, B; Prados, D; Quesada, JA; Rodríguez, JN | 1 |
| Kusama, H; Matsuoka, T; Ohsaka, A; Taguchi, H; Takagi, S | 1 |
| Ito, T; Konishi, H; Maesako, Y; Mori, S; Ueda, Y; Yagiri, Y | 1 |
| Advani, SH; Nair, CN; Nair, R | 1 |
| Cosson, A; Fenaux, P; Grardel, N; Lepelley, P; Poulain, S; Preudhomme, C | 1 |
| Eriksson, M; Hast, R; Jakovleva, K | 1 |
| Armata, J; Bogusławska-Jaworska, J; Chybicka, A; Eliasińska, A; Jackowska, T; Klus, K; Kowalczyk, J; Kołecki, P; Krauze, A; Matysiak, M; Pietras, W; Rokicka-Milewska, R; Stefańska, K; Wiśniewska-Slusarz, H; Wójcik, D | 1 |
| Hagiwara, S; Hirano, N; Miwa, A; Takezako, N; Togawa, A; Yuo, A | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Brice, P; Brion, A; Buzyn, A; Caillot, D; Cordonnier, C; Desablens, B; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hecquet, B; Hoang-Ngoc, L; Ifrah, N; Janvier, M; Lioure, B; Mahé, B; Maloisel, F; Milpied, N; Rochant, H; Sadoun, A; Solary, E; Stamatoulas, A; Stoppa, AM; Tilly, H; Wattel, E | 1 |
| Cheson, BD | 1 |
| Ferrini, PR; Santini, V | 1 |
| Burke, PJ; Cowan, K; Gore, SD; Jones, RJ; Piantadosi, S; Weng, LJ; Zilcha, M | 1 |
| Hara, T; Moriwaki, H; Oyama, M; Sawada, M; Tsurumi, H; Yamada, T | 1 |
| Aul, C; Germing, U; Giagounidis, AA; Giagounidis, AS; Koch, JA | 1 |
| Estey, EH | 1 |
| Engelhardt, R; Grotz, W; Lübbert, M; Rump, LC; Würthner, J | 1 |
| Bowen, DT; Tauro, S | 1 |
| Andreeff, M; Beran, M; Cortes, J; Estey, EH; Freireich, E; Kantarjian, H; Keating, MJ; Pierce, S; Thall, PF | 1 |
| Brice, P; Brion, A; Casassus, P; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hoang-Ngoc, L; Janvier, M; Jouet, JP; Leleu, X; Lepelley, P; Maloisel, F; Rochant, H; Solary, E; Wattel, E | 1 |
| Fujisawa, S; Fujita, H; Kanamori, H; Koharazawa, H; Matsuzaki, M; Mishima, A; Mohri, H; Murata, T; Tanaka, M; Yamaji, S | 1 |
| Hanada, R; Kikuchi, A; Ohashi, H; Yamamoto, K | 1 |
| Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B | 1 |
| Aoba, M; Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Matsuzaki, M; Mohri, H; Murata, T; Tanaka, M; Togawa, J | 1 |
| Daenen, SM; Löwenberg, B; Ossenkoppele, GJ; Sonneveld, P; van der Holt, B; van der Lelie, J; van Putten, WL; Verdonck, LF; Verhoef, GE; Wijermans, PW | 1 |
| Kuriyama, K; Mori, H | 1 |
| Letendre, L; Li, CY; Litzow, MR; Noel, P; Schroeder, G; Tefferi, A; White, WL | 1 |
| Abgrall, JP; Brice, P; Brion, A; Caillot, D; Cordonnier, C; Desablens, B; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hecquet, B; Hoang-Ngoc, L; Ifrah, N; Janvier, M; Leporrier, M; Lioure, B; Milpied, N; Pignon, B; Rochant, H; Sadoun, A; Solary, E; Stoppa, AM; Tilly, H; Veil, A; Wattel, E | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Pallis, M; Russell, NH; Syan, J | 1 |
| Beran, M; Kantarjian, H | 1 |
| Bergmann, L; Brack, N; Brockhaus, W; Fischer, JT; Fuhr, HG; Ganser, A; Heil, G; Hoelzer, D; Höffken, K; Hofmann, W; Ittel, TH; Knuth, P; Kolbe, K; Langer, W; Seipelt, G | 1 |
| Ohno, R; Takeshita, A | 1 |
| Fukuno, K; Goto, H; Hara, T; Moriwaki, H; Oyama, M; Tsurumi, H; Yamada, T | 1 |
| Aloe Spiriti, MA; Betrò, P; Breccia, M; D'Elia, GM; Latagliata, R; Luzi, G; Montefusco, E; Petti, MC; Pulsoni, A; Spadea, A | 1 |
| Akiyama, Y; Eguchi, M; Hayashi, Y; Hosoi, G; Ishii, E; Kato, K; Koike, K; Kojima, S; Nishimura, S; Ohara, A; Okamura, J; Okimoto, Y; Sako, M; Sato, T; Tsukimoto, I; Ueda, K; Yazaki, M; Yoshikawa, T | 1 |
| Abruzzese, E; Amadori, S; Buccisano, F; Cox, MC; Del Poeta, G; Masi, M; Maurillo, L; Scimò, MT; Tamburini, A; Tribalto, M; Venditti, A | 1 |
| Kajiguchi, T; Miyata, Y; Saito, M; Takeyama, H | 1 |
| Chiba, K; Fukuhara, T; Hirano, T; Kakinoki, Y; Kurosawa, M; Maekawa, I; Miyake, T; Mori, A; Morioka, M; Noto, S; Okabe, M; Suzuki, S; Toyoshima, T; Tsutsumi, Y | 1 |
| Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H | 1 |
| Arima, N; Fukushima, T; Kanamaru, A; Kishimoto, Y; Kusumoto, GS; Motoji, T; Ohno, R; Okamoto, T; Shimazaki, C; Takahashi, M; Takemoto, Y; Takeshita, A; Tsukuda, K; Uike, N; Yorimitsu, S | 1 |
| Aivado, M; Aul, C; Gattermann, N; Germing, U; Haas, R; Kobbe, G; Rieth, C; Rong, A | 1 |
| Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
| Akiyoshi, K; Eguchi, H; Hara, T; Inada, H; Ishii, E; Koga, H; Matsuzaki, A; Miyazaki, S; Nagatoshi, Y; Nakayama, H; Nibu, K; Okamura, J; Take, H; Tamai, Y; Yanai, F | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Calasanz, MJ; Gesk, S; Grote, W; Harder, L; Martín-Subero, JI; Novo, FJ; Schlegelberger, B; Schoch, R; Siebert, R | 1 |
| Bennett, JM; Dewald, GW; Friedenberg, WR; Hayes, FA; Hiddemann, W; Lazarus, HM; Liesveld, JL; Marsh, RD; Miller, KB; Paietta, E; Rowe, JM; Saba, HT; Young, MS | 1 |
| Balleari, E; Beltrami, G; Canepa, L; Carrara, P; Cerri, R; Clavio, M; Damasio, E; Gatto, S; Ghio, R; Gobbi, M; Masoudi, B; Miglino, M; Pierri, I; Sessarego, M | 1 |
| Asano, S; Iseki, T; Ito, K; Nagayama, H; Ooi, J; Shirafuji, N; Tani, K; Tojo, A; Tomonari, A | 1 |
| Amadori, S; Archimbaud, E; Aul, C; Boogaerts, M; de Witte, T; Ferrant, A; Gratwohl, A; Hagemeijer, A; Jehn, U; Labar, B; Mandelli, F; Muus, P; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R; Zwierzina, H | 1 |
| Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
| Hahn, JS; Jang, JH; Ko, YW; Lee, ST; Min, YH; Suh, HC | 1 |
| Gati, WP; Larratt, LM; Turner, AR | 1 |
| Iwakiri, R; Kumakawa, T; Mikoshiba, M; Mori, M; Ohta, M; Tsutsumi, H | 1 |
| Beran, M; Cortes, JE; Estey, EH; Giles, FJ; Kantarjian, HM; Pierce, SA; Thall, PF; Thomas, DA; Wang, XM | 1 |
| Eder, M; Ganser, A; Geissler, G; Hess, U; Hoelzer, D; Ottmann, OG; Seipelt, G | 1 |
| Alberto, P; Mermillod, B; Zulian, GB | 1 |
| Bennett, JM; Cassileth, PA; Head, DR; Kim, K; Kyungmann, K; Miller, KB; Morrison, FS; Neiman, RS; O'Connell, MJ; Winter, JN | 1 |
| Asprou, N; Bouronikou, H; Chalevelakis, G; Dervenoulas, J; Economopoulos, T; Karmas, P; Papageorgiou, E; Raptis, S; Stathakis, N | 1 |
| De Laurenzi, A; De Rosa, L; Montuoro, A | 1 |
| Chen, PH; Huang, CH; Kuo, CY; Shih, LY | 1 |
| el-Mangoush, M; Singh, NK | 1 |
| Cronin, S; Dan, ME; de Planque, MM; Karanes, C; Leisz, MC; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J | 1 |
| Lipschitz, DA; Mansouri, A | 1 |
| Aul, C; Gattermann, N | 1 |
| Neuwirtová, R | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W | 1 |
| Kawano, F; Nishimura, Y; Sanada, I; Satoh, M; Shido, T; Tsukamoto, A | 1 |
| Gerhartz, H | 1 |
| Antin, JH; Bierer, BE; Blythman, H; Bouloux, C; Ferrara, J; Guinan, EC; Macklis, RM; Provost, MM; Smith, BR; Tarbell, NJ | 1 |
| Alfano, G; Candido, A; Mancini, R; Mango, G; Menichella, G; Rossi, PL; Tartaglione, R | 1 |
| Hotta, T | 1 |
| Mufti, GJ; Schmalzl, F; Zwierzina, H | 1 |
| Hus, M; Kowalewski, J; Kurowska, M; Pluta, A; Spiewak, H | 1 |
| Smith, JG; Smith, MA | 1 |
| Huijgens, PC; Langenhuijsen, MM; Nauta, JJ; Ossenkoppele, GJ; Wijermans, PW | 1 |
| Ganser, A; Herrmann, F; Hoelzer, D; Lindemann, A; Mertelsmann, R; Oster, W; Ottmann, OG; Seipelt, G | 1 |
| Hotta, T; Ichikawa, A; Inoue, C; Murate, T; Saito, H; Tsushita, K | 1 |
| Goto, S; Hotta, T; Ichihara, M; Ichikawa, A; Kagami, Y; Murate, T; Ohashi, H; Takagi, N; Tsushita, K; Yamao, H | 1 |
| Farhi, DC; Rosenthal, NS | 1 |
| Fukawa, H; Harano, H; Hashimoto, Y; Kanamori, H; Kodama, F; Maruta, A; Matsuzaki, M; Miyashita, H; Murata, T; Noguchi, T | 1 |
| Biliczki, F; Bozóky, G | 1 |
| Ganser, A; Hoelzer, D; Seipelt, G | 1 |
| Crocker, I; Dobbs, CK; Gordon, DS; Heffner, LT; Reynolds, R; Sternberg, P; Vogler, WR; Winton, EF | 1 |
| Gotoh, T; Kosaka, M; Okagawa, K; Shinohara, M; Takishita, M; Tuchihashi, N; Wada, M | 1 |
| Becher, R; Boogaerts, MA; Diehl, V; Ganser, A; Hoelzer, D; Höffken, K; Krieger, O; Lathan, B; Lutz, D; Ottmann, OG | 1 |
| Cadiou, M; Delmer, A; Gerhartz, H; Karmochkine, M; Zittoun, R | 1 |
| Flasshove, M; Ganser, A; Grothey, A; Hoelzer, D; Höffken, K; Overkamp, F; Stirbu, J | 1 |
| Degos, L | 2 |
| Aul, C; Heyll, A | 1 |
| Billström, R; Carneskog, J; Grimfors, G; Hellström, E; Kimby, E; Lindemalm, C; Oberg, G; Robèrt, KH; Samuelsson, J; Winqvist, I | 1 |
| Smith, JG; Smith, MA; Taylor, PC | 1 |
| Bär, BM; de Pauw, BE; de Witte, T; Haanen, C | 1 |
| Aul, C; Schneider, W | 2 |
| Cosson, A; Estienne, MH; Fenaux, P; Lai, JL; Lepelley, P; Preudhomme, C; Zandecki, M | 1 |
| Cepelák, V; Koza, V; Masek, Z; Neuwirtová, R; Vozobulová, V | 1 |
| De Pauw, B; De Witte, T; Haanen, C; Muus, P | 1 |
| Frydecka, I; Kotlerek-Haus, S; Kuliczkowski, K; Nowicka, J; Sedek, K | 1 |
| Yoshida, Y | 1 |
| Buschle, M; Drexler, HG; Heimpel, H; Janssen, JW; Kleihauer, E; Kubanek, B; Layton, M; Lyons, J; Mufti, GJ; van den Berghe, H | 1 |
| Bartram, CR; Buschle, M; Janssen, JW; Layton, M; Lyons, J | 1 |
| Amenomori, T; Ichimaru, M; Jinnai, I; Kuriyama, K; Matsuo, T; Nonaka, H; Sadamori, N; Sasagawa, I; Tomonaga, M; Yoshida, Y | 1 |
| Huijgens, PC; Langenhuijsen, MM; Ossenkoppele, GJ; van Geel, BM; Wijermans, PW | 1 |
| Gahrton, G; Hellström, E; Ost, A; Putkonen, PO; Robèrt, KH; Soppi, E | 1 |
| Advani, SH; Das Gupta, A; Dole, MG; Giri, NK; Gopal, R; Kurkure, PA; Nair, CN; Pai, SK; Pai, VR; Saikia, TK | 1 |
| Drzewoski, J; Jerzmanowski, P; Koźbiał, H; Krykowski, E; Kusowska, J; Robak, T | 1 |
| el Mangoush, M; Gamati, A; Korajkio, M; Kumar, S; Singh, MK | 1 |
| Baro, J; Bello, C; Conde, E; Cuadrado, MA; Garijo, J; Iriondo, A; Recio, M; Richard, C; Zubizarreta, A | 1 |
| Guinan, EC; Tantravahi, R; Tarbell, NJ; Weinstein, HJ | 1 |
| Goldstone, AH; Gribben, JG; Linch, DC; MacMillan, AK; Richards, JD | 1 |
| Ganser, A; Hoelzer, D; Ottmann, OG; Schulz, G | 1 |
| Bogdanić, V; Labar, B; Mrsić, M; Nemet, D; Serventi-Seiwerth, R | 1 |
| Baumelou, M; Delmer, A; Fière, D; Gerhartz, HH; Jacobs, A; Labar, B; Marcus, R; Ribeiro, M; Visani, G; Zwierzina, H | 1 |
| Bosković, D; Elezović, I; Gotić, M; Janosević, S; Mijović, A; Rolović, Z; Tomin, D | 1 |
| Abe, T; Fujii, H; Horiike, S; Inazawa, J; Misawa, S; Nakagawa, H; Sonoda, Y; Tanaka, S; Taniwaki, M; Tsuda, S | 1 |
| Ichimaru, M; Jinnai, I; Kuriyama, K; Nonaka, H; Sadamori, N; Tagawa, M; Tokunaga, K; Tomonaga, M; Yoshida, Y | 1 |
| Ferrant, A; Martiat, P; Michaux, JL; Mineur, P | 2 |
| Appelbaum, FR; Hoffman, R; Jansen, J; Lauer, RC; Tricot, GJ | 1 |
| Cheong, SK | 1 |
| Mitsutani, S | 1 |
| Copplestone, JA; Hamblin, TJ; Mufti, GJ; Oscier, DG; Worsley, A | 1 |
| Layton, DM; Mufti, GJ; Pagliuca, A | 1 |
| Ganser, A; Greher, J; Hoelzer, D; Völkers, B; Walther, F | 1 |
| Firkin, FC; Januszewicz, EH | 1 |
| Cacciola, E; Di Raimondo, F; Giustolisi, R; Guglielmo, P; Milone, G | 1 |
| Baumelou, E; Calvo, F; Casassus, P; Chomienne, C; Ciccone, F; Degos, L; Fenaux, P; Gris, JC; Najean, Y; Thomas, G | 1 |
| Freireich, EJ | 1 |
| Kuriyama, K | 1 |
| Daly, KM; Larson, RA; Le Beau, MM; Pape, LH; Rowley, JD; Vardiman, JW; Wernli, M | 1 |
| Lawlor, E; McCann, SR; Murray, M; Sarsfield, P | 1 |
| Dohy, H; Kyo, T | 2 |
| Bartram, CR; Janssen, JW; Layton, DM; Lyons, J; Mufti, GJ | 1 |
| Clark, RE; Ismail, SA; Jacobs, A; Payne, H; Smith, SA | 1 |
| Bolwell, BJ; Cassileth, PA; Gale, RP | 1 |
| Ho, AD; Hunstein, W; Knauf, W; Martin, H; Reichardt, P; Trümper, L | 1 |
| Bearden, JD; Buss, DH; Capizzi, RL; Connelly, RA; Jackson, DV; Lyerly, ES; Muss, HB; Powell, BL; Richards, F; Rosenbaum, DL | 1 |
| Bennett, JM; Owens, MR | 1 |
| Frick, P; Jacky, E | 1 |
| Iavorkovskiĭ, LI; Iavorkovskiĭ, LL; Riauzova, LIu; Soloveĭ, DIa; Udris, OIu | 1 |
| Björkholm, M; Einhorn, S; Gahrton, G; Grimfors, G; Hellström, E; Lindemalm, C; Mellstedt, H; Robèrt, KH; Samuelsson, J; Udén, AM | 1 |
| Kimura, K; Ohno, R | 1 |
| Harano, H; Kanamori, H; Kodama, F; Maruta, A; Matsuzaki, M; Miyashita, H; Motomura, S; Noguchi, T; Ogawa, K; Takahashi, K | 1 |
| Abe, T; Akasaka, K; Inamoto, Y; Ishikura, H; Izumi, Y; Katoh, Y; Okada, H; Okazaki, T; Sawada, H; Usui, T | 1 |
| Cantù-Rajnoldi, A; Conter, V; Creutzig, U; Masera, G; Odenwald, E; Riehm, H; Ritter, J; Romitti, L | 1 |
| Hammerstrøm, J; Hoff, JE; Langtind, J; Lødemel, B; Waage, A | 1 |
| Horiuchi, A; Kanamaru, A; Kitani, T; Kohsaki, M; Masaoka, T; Nagai, K; Shibata, H; Tagawa, S; Tsubaki, K; Yasunaga, K | 1 |
| Delacrétaz, F; Mermillod, B; Piguet, D; Schmidt, PM | 1 |
| Audhuy, B; Barats, JC; Blaise, AM; Boilletot, A; Flesch, M; Herbrecht, R; Pignon, B; Rozenbaum, A | 1 |
| Katayama, N; Minami, N; Shirakawa, S; Tanaka, I | 1 |
| Aul, C; Heyll, A; Heyll, U; Schneider, W | 1 |
| Ota, K | 1 |
| Morioka, E; Niho, Y; Ohhara, N; Okamura, S; Shibuya, T; Taniguchi, S | 1 |
| Berney, JJ; Francis, GE; Guimaraes, JE; Hamblin, TJ; Knowles, SM; Mufti, GJ; Secker-Walker, LM | 1 |
| Boogaerts, MA; Tricot, G; Verwilghen, RL | 1 |
| Buzaid, AC; Garewal, HS; Greenberg, BR | 1 |
| Azarnia, N; Barcos, M; Browman, G; D'Arrigo, P; Grunwald, H; Larson, R; Preisler, HD; Raza, A; Stein, A; Walker, I | 1 |
| Cheson, BD; Friedman, MA; Jasperse, DM; Simon, R | 1 |
| Kufe, DW; Spriggs, DR; Stone, RM | 1 |
| Fabian, I; Nagler, A; Riklis, I; Tatarsky, I | 1 |
| Akashi, M; Akutsu, M; Furukawa, Y; Ikeda, K; Komatsu, N; Muroi, K; Ohsaka, A; Takeda, K; Tsunoda, S; Yoshida, M | 1 |
| Baccarani, M; Fanin, R; Fasola, G; Motta, MR; Poluzzi, C; Rizzi, S; Tura, S | 1 |
| Bailey-Wood, R; Clark, RE; Dallimore, CM; Jacobs, A | 1 |
| Cheson, BD; Simon, R | 1 |
| Kimura, K | 1 |
| Abbadessa, A; Arcidiacone, G; Bruzzese, L; Ottaiano, L | 1 |
| Hirano, M; Hirota, Y; Ikeda, Y; Kobayashi, M; Mitomo, Y; Ohara, K; Ohno, R; Shirakawa, S; Yamagata, K; Yoshikawa, S | 1 |
| Boogaerts, MA; Tricot, G | 1 |
| García de la Fuente, A; Gilsanz Fernández, C; Guisasola Zulueta, MC; Tintó del Val, JA | 1 |
| Kawano, F | 1 |
| Sawada, H | 1 |
| Ho, AD; Hunstein, W; Schwarz, CE | 1 |
| Bron, D; Debusscher, L; Stryckmans, P | 1 |
| Barcos, M; Preisler, HD; Raza, A | 1 |
61 review(s) available for cytarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Sulfonamides | 2022 |
Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
CPX-351 (vyxeos) in AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis | 2020 |
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Topics: Administration, Oral; Allografts; Antineoplastic Agents; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Risk Assessment; Stem Cell Transplantation; Survival Rate | 2020 |
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines | 2020 |
CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Topics: Age Factors; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Middle Aged; Mutation; Myelodysplastic Syndromes | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Combinations; Drug Interactions; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes | 2018 |
Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myelodysplastic Syndromes; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Glasdegib: First Global Approval.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Drug Approval; Europe; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Signal Transduction; United States | 2019 |
[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2019 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Clofarabine in the treatment of myelodysplastic syndromes.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Myelodysplastic Syndromes | 2014 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Hypomethylating agents and chemotherapy in MDS.
Topics: Allografts; Anthracyclines; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Stem Cell Transplantation | 2013 |
Translocation t(11;19)(q23;q13.1) without MLL Rearrangement in Acute Myeloid Leukemia: Heterogeneity of the 11q23 Breakpoints.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 19; Cytarabine; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Translocation, Genetic | 2015 |
HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Granulocytic sarcoma in a patient with myelodysplastic syndrome.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Fatal Outcome; Female; Humans; Myelodysplastic Syndromes; Sarcoma, Myeloid | 2008 |
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2011 |
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile | 2012 |
Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?
Topics: Antimetabolites, Antineoplastic; Cytarabine; Dose-Response Relationship, Drug; Humans; Myelodysplastic Syndromes | 2004 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 5; Cytarabine; Cytogenetic Analysis; Etoposide; Fatal Outcome; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2005 |
The role of bone marrow transplantation in the treatment of myelodysplastic syndromes.
Topics: Bone Marrow Transplantation; Calcitriol; Cytarabine; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Isotretinoin; Myelodysplastic Syndromes; Prognosis; Transplantation, Homologous | 1995 |
Differentiation therapy of myelodysplastic syndromes with retinoic acid.
Topics: Clinical Trials as Topic; Cytarabine; Humans; Myelodysplastic Syndromes; Tretinoin | 1994 |
Long term remission of acute myeloid leukaemia with trilineage myelodysplasia treated solely with low dose cytarabine.
Topics: Acute Disease; Cytarabine; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Time Factors | 1994 |
[Differentiating agents in myelodysplastic syndromes. Analysis of personal cases].
Topics: Aged; Anemia, Myelophthisic; Anemia, Refractory, with Excess of Blasts; Colony-Stimulating Factors; Cytarabine; Female; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Myelomonocytic, Chronic; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes | 1993 |
Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid; Middle Aged; Morbidity; Myelodysplastic Syndromes; Survival Rate | 1996 |
Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
Topics: Cytarabine; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Myelodysplastic Syndromes | 1996 |
Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes.
Topics: Aged; Cytarabine; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interleukin-3; Interleukin-6; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 1997 |
Clinical use of hematopoietic growth factors in the myelodysplastic syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Interleukin-6; Myelodysplastic Syndromes; Prognosis | 1997 |
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.
Topics: Anthracyclines; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Harringtonines; Homoharringtonine; Humans; Myelodysplastic Syndromes; Pyrimidines; Topotecan | 1998 |
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arginine; Azacitidine; Butyrates; Cholecalciferol; Cytarabine; Harringtonines; Hematopoietic Cell Growth Factors; Heme; Homoharringtonine; Humans; Interferons; Myelodysplastic Syndromes; Retinoids | 1998 |
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
[Diagnosis and therapy of myelodysplastic syndrome].
Topics: Blood Transfusion; Bone Marrow Transplantation; Cholecalciferol; Cytarabine; Cytokines; Diagnosis, Differential; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes | 1999 |
[New combination therapies in hematological malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporins; Cytarabine; Doxorubicin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Myelodysplastic Syndromes; Prednisone; Quinolines; Rituximab; Tretinoin; Vidarabine; Vincristine | 2000 |
Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Height; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Growth Disorders; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Infant; Japan; Male; Methotrexate; Myelodysplastic Syndromes; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Survivors; Treatment Outcome; Vincristine | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Myelodysplastic Syndromes | 1992 |
Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Topics: Cytarabine; Drug Synergism; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Myelodysplastic Syndromes | 1992 |
Myelodysplastic syndromes in the elderly.
Topics: Aged; Bone Marrow Transplantation; Cause of Death; Clinical Protocols; Cytarabine; Decision Trees; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Prognosis; Survival Rate | 1992 |
The role of low-dose chemotherapy in myelodysplastic syndromes.
Topics: Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Humans; Myelodysplastic Syndromes | 1992 |
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Vidarabine | 1992 |
[Management of myelodysplastic syndromes].
Topics: Bone Transplantation; Cholecalciferol; Colony-Stimulating Factors; Cytarabine; Danazol; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Immunologic Factors; Isotretinoin; Myelodysplastic Syndromes | 1990 |
[Therapeutic possibilities in the treatment of the myelodysplasia syndrome].
Topics: Age Factors; Anemia, Sideroblastic; Antineoplastic Agents; Blastomeres; Bone Marrow Transplantation; Cytarabine; Hematopoiesis; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes | 1991 |
The role of GM-CSF, G-CSF, interleukin-3, and erythropoietin in myelodysplastic syndromes.
Topics: Clone Cells; Cytarabine; Drug Synergism; Erythrocyte Count; Hematopoietic Cell Growth Factors; Humans; Myelodysplastic Syndromes; Neutrophils; Platelet Count | 1991 |
Differentiating agents in the treatment of leukemia.
Topics: Cell Differentiation; Cytarabine; Humans; Interferon Type I; Leukemia; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Tretinoin | 1990 |
Differentiating agents in the treatment of leukemia and myelodysplastic syndromes.
Topics: Cell Differentiation; Cell Division; Cytarabine; Humans; Interferon Type I; Leukemia; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Tretinoin | 1990 |
[The therapy of myelodysplastic syndromes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Differentiation; Combined Modality Therapy; Cytarabine; Cytokines; Humans; Myelodysplastic Syndromes; Steroids; Vitamins | 1990 |
Management of the myelodysplastic syndromes.
Topics: Bone Marrow Transplantation; Cholecalciferol; Combined Modality Therapy; Cytarabine; Hormones; Humans; Myelodysplastic Syndromes; Tretinoin | 1987 |
Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible?
Topics: Cell Differentiation; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Tretinoin | 1988 |
Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature.
Topics: Aged; Cell Differentiation; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Fluoxymesterone; Humans; Middle Aged; Myelodysplastic Syndromes | 1987 |
New strategies in the management of acute leukemias.
Topics: Acute Disease; Amsacrine; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphoid; Myelodysplastic Syndromes; Prognosis; Remission Induction | 1987 |
Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
Topics: Age Factors; Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 1987 |
Treatment of patients with myelodysplastic syndromes: a review.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Cell Differentiation; Child, Preschool; Cytarabine; Drug Therapy, Combination; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin; Vitamin D | 1986 |
Management of myelodysplastic syndromes.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Danazol; Glucocorticoids; Humans; Isotretinoin; Myelodysplastic Syndromes; Pyridoxal Phosphate; Pyridoxine; Tretinoin | 1986 |
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Bone Marrow; Child; Cytarabine; Follow-Up Studies; Humans; Leukemia; Leukocyte Count; Middle Aged; Myelodysplastic Syndromes; Platelet Count | 1986 |
The treatment of myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Blood Transfusion; Bone Marrow Transplantation; Cytarabine; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Prognosis | 1986 |
135 trial(s) available for cytarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Triazoles | 2022 |
A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Aclarubicin; Adult; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Myelodysplastic Syndromes; Recurrence | 2023 |
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Topics: Adult; Aged; Cytarabine; Daunorubicin; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; United Kingdom | 2023 |
The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Treatment Outcome | 2019 |
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2020 |
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Sulfonamides; Survival Rate | 2020 |
Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diphosphates; Drug Resistance, Neoplasm; Drug Synergism; Feasibility Studies; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prodrugs; Respiratory Distress Syndrome; Salvage Therapy; Stilbenes; Treatment Outcome; Young Adult | 2020 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Topics: Aged; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes | 2021 |
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Azacitidine; Benzothiazoles; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Disease-Free Survival; Down Syndrome; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm, Residual; Treatment Outcome | 2017 |
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Co
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Child; Child, Preschool; Cyclams; Cytarabine; Etoposide; Female; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, CXCR4; Treatment Outcome; Young Adult | 2017 |
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2017 |
Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2018 |
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Cytarabine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Phenylurea Compounds; Prognosis; Survival Rate | 2019 |
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Treatment Outcome | 2013 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome | 2014 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Hematopoietic stem cell transplantation in children with refractory cytopenia of childhood: single-center experience using high-dose cytarabine containing myeloablative and aplastic anemia oriented reduced-intensity conditioning regimens.
Topics: Adolescent; Adult; Anemia, Aplastic; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Myelodysplastic Syndromes; Survival Rate; Transplantation Conditioning | 2015 |
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Young Adult | 2015 |
Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pravastatin; Risk Factors; Survival Rate | 2015 |
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate | 2015 |
Long-term outcomes of granulocyte colony-stimulating factor-combined conditioning in allogeneic hematopoietic stem cell transplantation from HLA-identical family donors for myeloid malignancies.
Topics: Adolescent; Adult; Allografts; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Family; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Whole-Body Irradiation | 2015 |
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).
Topics: Adolescent; Adult; Aged; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Disease-Free Survival; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 2015 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Vincristine | 2016 |
Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bicycling; Cognitive Dysfunction; Cytarabine; Executive Function; Exercise Therapy; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neuropsychological Tests; Spatial Memory; Treatment Outcome | 2016 |
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; DNA Methylation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms; Treatment Outcome | 2017 |
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Random Allocation; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2017 |
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Survival Rate | 2008 |
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult | 2009 |
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Cytogenetic Analysis; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2009 |
[A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Young Adult | 2009 |
[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2009 |
Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Disease Progression; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Treatment Outcome; Young Adult | 2009 |
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2010 |
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2010 |
Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
Topics: Aclarubicin; Adult; Aged; Cytarabine; Drug Combinations; Female; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2010 |
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Oxides; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoadjuvant Therapy; Neoplasm Staging; Quinolones; Remission Induction; Risk; Young Adult | 2011 |
Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2010 |
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Recurrence; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
[Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Young Adult | 2012 |
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome | 2012 |
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies | 2013 |
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infections; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Survival Rate; Thioguanine | 2003 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Disease-Free Survival; Etoposide; Female; Genes, MDR; Humans; Logistic Models; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Myelodysplastic Syndromes; Survival Analysis; United States | 2004 |
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Risk Factors; Survival Rate; Vidarabine | 2004 |
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Topotecan; Treatment Outcome | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Female; Hemoglobinometry; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Survival Analysis; Time Factors; Vidarabine | 2004 |
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Models, Chemical; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Nucleosides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2004 |
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Interleukin-11; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Analysis | 2005 |
Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Interleukin-3; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Treatment Outcome | 2005 |
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Pyridines; Recurrence; Risk Factors; Thiosemicarbazones; Treatment Outcome | 2006 |
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Remission Induction; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2006 |
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Stem Cell Factor; Survival Rate; Treatment Outcome | 2007 |
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival; Treatment Outcome; Tretinoin | 2007 |
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatmen
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Europe; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pilot Projects; Prognosis; Prospective Studies; Survival Analysis | 1995 |
Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Remission Induction; Vidarabine | 1993 |
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyt
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Regression Analysis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 1994 |
Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Remission Induction | 1994 |
Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1993 |
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Topics: Anemia, Refractory; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Methotrexate; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Thioguanine | 1994 |
[Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
Topics: Blood Cell Count; Bone Marrow; Cell Differentiation; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Hematopoiesis; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Remission Induction; Tretinoin | 1994 |
A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Risk Factors | 1994 |
Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate | 1993 |
A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Blood Component Transfusion; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Probability; Survival Analysis | 1993 |
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cytarabine; Drug Resistance, Neoplasm; Female; Hemorrhage; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Remission Induction; Sepsis; Treatment Failure; Vidarabine | 1996 |
Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF).
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cytarabine; Drug Synergism; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors | 1996 |
Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Hematopoiesis; Humans; Interleukin-3; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Survival Rate; Time Factors | 1996 |
Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Myelodysplastic Syndromes; Platelet Count; Remission Induction; Thioguanine; Treatment Outcome | 1996 |
[Low-dose chemotherapy].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction | 1996 |
[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Differentiation; Cytarabine; fas Receptor; Humans; Myelodysplastic Syndromes | 1996 |
Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Prospective Studies | 1997 |
Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Immunosuppressive Agents; Male; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medica
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome | 1997 |
Clonality analysis as a tool to study the biology and response to therapy in myelodysplastic syndromes.
Topics: Blotting, Southern; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Female; Gene Rearrangement; Genetic Markers; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Probability; Prognosis; Recombinant Proteins; Survival Rate; Time Factors | 1997 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Blood; Candida; Central Nervous System Diseases; Cytarabine; Double-Blind Method; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Risk Factors | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors | 1997 |
[A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors | 1998 |
All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prospective Studies; Treatment Outcome; Tretinoin | 1998 |
Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Danazol; Disease Progression; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Life Tables; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Quinine; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vault Ribonucleoprotein Particles | 1998 |
[Treatment outcome for myelodysplastic syndromes (MDS) obtained by the Polish Children's Leukemia/Lymphoma Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Male; Mercaptopurine; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid | 1998 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Quinine; Survival Rate; Treatment Outcome | 1998 |
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Growth Factor; Remission Induction | 1995 |
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Probability; Prognosis; Survival Rate; Time Factors; Tretinoin; Vidarabine | 1999 |
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk Factors; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Evaluation Studies as Topic; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Tests; Humans; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neutropenia; Placebos; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 1999 |
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Remission Induction | 1999 |
Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cytarabine; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Tretinoin | 1999 |
Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Français des Myélodysplasies (GFM) and Groupe GOELAMS.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Disease Progression; Female; Genes, MDR; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Phenotype; Quinine; Remission Induction; Survival Analysis | 1999 |
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Platelet Count; Remission Induction; Risk Assessment; Survival Rate; Thrombocytopenia; Topotecan | 1999 |
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Immunotherapy; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate | 2000 |
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Probability; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2000 |
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia; Tretinoin | 2000 |
Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Survival Rate; Treatment Outcome | 2000 |
Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced Liver Injury; Cytarabine; DNA Replication; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Pancytopenia; Pilot Projects; Recombinant Proteins; Remission Induction; S Phase; Treatment Failure | 2001 |
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Survival Rate; Vidarabine | 2001 |
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2001 |
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Topics: Acute Disease; Aged; Aged, 80 and over; Aminoglycosides; Anemia, Refractory, with Excess of Blasts; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Cytarabine; Drug Therapy, Combination; Gemtuzumab; Humans; Idarubicin; Immunotoxins; Infusions, Parenteral; Interleukin-11; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Therapeutic Equivalency | 2002 |
The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1992 |
Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside.
Topics: Aged; Blood Cell Count; Cytarabine; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1992 |
[Growth factors in therapy of life threatening leukopenia].
Topics: Cytarabine; Drug Evaluation; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neutropenia; Recombinant Proteins | 1992 |
Clinical use of recombinant human hematopoietic growth factors (GM-CSF, IL-3, EPO) in patients with myelodysplastic syndrome.
Topics: Blood Cell Count; Cytarabine; Erythropoietin; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Interleukin-3; Myelodysplastic Syndromes; Recombinant Proteins | 1991 |
Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.
Topics: Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Hematopoiesis; Humans; Injections, Subcutaneous; Leukocyte Count; Multicenter Studies as Topic; Myelodysplastic Syndromes; Recombinant Proteins | 1990 |
Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
Topics: Aged; Aged, 80 and over; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Tretinoin | 1990 |
Low-dose Ara-C in the treatment of myelodysplastic syndromes.
Topics: Cytarabine; Humans; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 1989 |
Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.
Topics: Adult; Aged; Aged, 80 and over; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic | 1989 |
Prognostic factors and treatment of myelodysplastic syndromes.
Topics: Aged; Alkaline Phosphatase; Cytarabine; Female; Humans; Leukocytes; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Randomized Controlled Trials as Topic | 1989 |
Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature.
Topics: Aged; Cell Differentiation; Cytarabine; Drug Evaluation; Drug Therapy, Combination; Fluoxymesterone; Humans; Middle Aged; Myelodysplastic Syndromes | 1987 |
A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cytarabine; Drug Therapy, Combination; Female; Humans; Isomerism; Male; Middle Aged; Myelodysplastic Syndromes; Random Allocation; Tretinoin | 1987 |
Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Topics: Adult; Aged; Cell Differentiation; Clinical Trials as Topic; Cytarabine; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Skin Diseases; Tretinoin | 1987 |
High-dose cytosine arabinoside in the treatment of preleukemic disorders: a leukemia intergroup study.
Topics: Adult; Aged; Clinical Trials as Topic; Cytarabine; Drug Administration Schedule; Humans; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Platelet Count; Preleukemia; Thrombocytopenia | 1986 |
259 other study(ies) available for cytarabine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Topics: Animals; Azacitidine; Cytarabine; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-hck | 2022 |
Treatment of myeloid neoplasia with doxorubicin and cytarabine in 11 dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Exosomal miR92a Promotes Cytarabine Resistance in Myelodysplastic Syndromes by Activating Wnt/β-catenin Signal Pathway.
Topics: beta Catenin; Cytarabine; Humans; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Wnt Signaling Pathway | 2022 |
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
Topics: Cytarabine; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Transplantation Conditioning | 2023 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes - Authors' reply.
Topics: Cytarabine; Daunorubicin; Humans; Myelodysplastic Syndromes | 2023 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes.
Topics: Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2023 |
Non-allogeneic immunotherapy in acute myeloid leukaemia.
Topics: Cytarabine; Humans; Idarubicin; Immunotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Nivolumab | 2019 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Clinical Trials, Phase II as Topic; Cytarabine; Drug Approval; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Phenylurea Compounds; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2019 |
Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Eruptions; Female; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes | 2020 |
Bilateral Acute Anterior Uveitis during Chemotherapy with Cytosine Arabinoside with a Total Cumulative Dose of 24 000 mg for Myelodysplastic Syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Myelodysplastic Syndromes; Uveitis, Anterior | 2020 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2020 |
Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Compassionate Use Trials; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Liposomes; Myelodysplastic Syndromes | 2021 |
AHR signaling pathway reshapes the metabolism of AML/MDS cells and potentially leads to cytarabine resistance.
Topics: Adult; Aged; Basic Helix-Loop-Helix Transcription Factors; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Receptors, Aryl Hydrocarbon; Signal Transduction; THP-1 Cells; U937 Cells | 2021 |
Clinical Characteristics and Optimal Therapy of Acute Myeloid Leukemia with Myelodysplasia-Related Changes: A Retrospective Analysis of a Cohort of Chinese Patients
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies | 2021 |
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC).
Topics: Adult; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cephalosporins; Cytarabine; Female; Gram-Positive Bacterial Infections; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Vancomycin; Vancomycin-Resistant Enterococci; Young Adult | 2017 |
Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin | 2017 |
Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Case-Control Studies; Cells, Cultured; Cholesterol, LDL; Cytarabine; Cytokines; DNA; DNA, Mitochondrial; Female; HLA-DR Antigens; Humans; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Leukocytes; Lipopolysaccharides; Male; Middle Aged; Myelodysplastic Syndromes; Young Adult | 2017 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Cells, Cultured; Cytarabine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Gene Expression Regulation; Gene Knockout Techniques; Genetic Loci; Humans; Immunohistochemistry; Mice; Mice, Knockout; Models, Biological; Myelodysplastic Syndromes; NF-E2-Related Factor 2; Protein Binding | 2019 |
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Red-Cell Aplasia, Pure; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2019 |
Selenium compounds induced ROS-dependent apoptosis in myelodysplasia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line; Cell Proliferation; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Membrane Potential, Mitochondrial; Mitochondria; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Selenium Compounds; Selenomethionine; Sodium Selenite; Superoxides | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission.
Topics: Adolescent; Adult; Biomarkers; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Blood Cell Count; Critical Care; Cyclophosphamide; Cytarabine; Daunorubicin; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunocompromised Host; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Retrospective Studies; Young Adult | 2014 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Methylation; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Homologous | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.
Topics: Antigens, CD34; Biomarkers; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cytarabine; Enzyme Activation; Erythropoiesis; Gene Expression; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; K562 Cells; MicroRNAs; Models, Biological; Multigene Family; Myelodysplastic Syndromes; Myeloid Differentiation Factor 88; NF-kappa B; Prognosis; Signal Transduction; Toll-Like Receptors | 2014 |
[Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fluconazole; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Myelodysplastic Syndromes; Pre-Exposure Prophylaxis; Remission Induction; Retrospective Studies; Survival Analysis; Triazoles | 2016 |
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cohort Studies; Cytarabine; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocytes; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Thrombocytopenia | 2015 |
Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2015 |
SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cytarabine; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Necrosis; Osteonectin; Protein Kinases | 2015 |
Gene expression profiling in myelodysplastic syndrome after SPARC overexpression associated with Ara-C.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Osteonectin; Up-Regulation | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).
Topics: Animals; Anthracyclines; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Cytidine Deaminase; DNA, Complementary; Gene Expression Regulation, Leukemic; Gene Transfer Techniques; Genetic Vectors; Hematopoietic Stem Cells; Humans; Lentivirus; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; RNA Splice Sites | 2015 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
[Comparison of Curative Effects of HAG and CAG Regimens for Patients with AML and Medium/High-Risk MDS].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction | 2016 |
Effect of granulocyte colony-stimulating factor priming combined with low-dose cytarabine and homoharringtonine in higher risk myelodysplastic syndrome patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Pilot Projects; Remission Induction; Risk; Young Adult | 2016 |
De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
Topics: Antimetabolites, Antineoplastic; Bone Marrow; Bone Marrow Cells; Case-Control Studies; Cell Line; Cell Proliferation; Cellular Microenvironment; Chemotaxis; Cytarabine; Cytokines; Female; Gene Expression Regulation; Gene Silencing; Humans; Immunomodulation; Leukemia, Myeloid, Acute; Male; MicroRNAs; Mitogen-Activated Protein Kinases; Myelodysplastic Syndromes; NF-kappa B; RNA Interference; Signal Transduction; T-Lymphocyte Subsets; Tumor Microenvironment | 2017 |
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Topics: Cell Count; Cell Death; Cell Survival; Cyclopentanes; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrimidines | 2017 |
[Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2008 |
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Homologous; Valproic Acid | 2009 |
Is survival enough for myelodysplastic syndromes?
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Homologous; Valproic Acid | 2009 |
[Curative effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2010 |
Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Chromosomes, Human, Pair 7; Combined Modality Therapy; Crohn Disease; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Monocytic, Acute; Male; Mercaptopurine; Mesalamine; Methyltransferases; Monosomy; Myelodysplastic Syndromes; Prednisone; Young Adult | 2010 |
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Trisomy; Young Adult | 2010 |
Prodrugs of aza nucleosides based on proton transfer reaction.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Design; Hydrogen Bonding; Kinetics; Myelodysplastic Syndromes; Nucleosides; Prodrugs; Protons; Thermodynamics | 2010 |
Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk | 2011 |
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |
Abnormal erythroid cell proliferation and myelofibrosis in a cat.
Topics: Anemia; Animals; Cat Diseases; Cats; Cell Proliferation; Cytarabine; Erythroid Cells; Fatal Outcome; Myelodysplastic Syndromes; Primary Myelofibrosis | 2012 |
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Topics: Aclarubicin; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2012 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Decitabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Ribosomal Proteins; Risk Factors; Treatment Outcome; Young Adult | 2012 |
[Genetic prognostic factors in childhood acute myeloid leukemia].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Cytarabine; DNA Mutational Analysis; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Genetic Markers; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Nuclear Proteins; Nucleophosmin; Prognosis; Survival Rate; Translocation, Genetic | 2012 |
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow Cells; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 11; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pelvis; Pregnancy; Pregnancy Complications, Neoplastic; Transplantation, Autologous | 2002 |
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction | 2003 |
Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Heart Transplantation; Humans; Idarubicin; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Postoperative Complications; Stem Cell Transplantation | 2002 |
[WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; WT1 Proteins | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13).
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 16; Cytarabine; Female; Gene Rearrangement; Histone Acetyltransferases; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae Proteins; Sequence Analysis, DNA; Translocation, Genetic | 2003 |
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Recombinant Proteins; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome; Vidarabine | 2002 |
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Idarubicin; Leukemia, Myeloid; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Successful treatment with intermediate dose cytosine arabinoside for myelodysplastic syndrome with acute myelofibrosis.
Topics: Acute Disease; Cytarabine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; Remission Induction; Treatment Outcome | 2003 |
Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Tretinoin | 2003 |
Protein 4.1 deficiency and deletion of chromosome 20q are associated with acquired elliptocytosis in myelodysplastic syndrome.
Topics: Aged; Anemia, Refractory; Antibiotics, Antineoplastic; Chromosome Deletion; Chromosomes, Human, Pair 20; Cytarabine; Cytoskeletal Proteins; Elliptocytosis, Hereditary; Erythrocytes; Humans; Idarubicin; Immunosuppressive Agents; Male; Membrane Proteins; Myelodysplastic Syndromes; Pancytopenia | 2004 |
Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cytarabine; Disease Progression; Female; Humans; Isotretinoin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine | 2004 |
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2004 |
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia; Myelodysplastic Syndromes; Vidarabine | 2004 |
A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Tretinoin | 2004 |
Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Hematologic Diseases; Humans; Karyotyping; L-Lactate Dehydrogenase; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recombinant Proteins; Retrospective Studies; Risk Assessment; Risk Factors | 2005 |
Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Treatment Outcome; Vidarabine | 2005 |
Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; DNA-Binding Proteins; DNA, Complementary; Drug Resistance, Neoplasm; Electroporation; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Proteins; Phenotype; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; Tumor Cells, Cultured | 2005 |
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 1989 |
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
Mycotic aneurysm of the distal aortic arch caused by Aspergillus.
Topics: Aged; Aneurysm, Infected; Antifungal Agents; Aortic Aneurysm, Thoracic; Aspergillosis; Blood Vessel Prosthesis Implantation; Cytarabine; Fatal Outcome; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Myelodysplastic Syndromes; Pancytopenia; Prednisolone | 2006 |
Excretion of cytosine arabinoside in saliva after its administration at high doses.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Saliva; Time Factors | 2006 |
Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Chromosomes, Human, Pair 1; Cytarabine; Daunorubicin; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cytarabine; Disease Progression; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2007 |
Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
Topics: 5'-Nucleotidase; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cytarabine; Deoxycytidine Kinase; Humans; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Precancerous Conditions; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
[Acute myelogenous leukemia with multilineage myelodysplasia, positive direct Coombs test, and elevated levels of platelet-associated IgG].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Coombs Test; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulin G; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pancytopenia; Prednisolone; Treatment Outcome | 2007 |
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2008 |
Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Keratoconjunctivitis; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2008 |
Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Topics: Aged; Antibiotics, Antineoplastic; Antigens, CD; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Carrier Proteins; Cohort Studies; Cytarabine; Drug Resistance; Drug Therapy, Combination; Humans; Immunohistochemistry; Immunophenotyping; Membrane Glycoproteins; Middle Aged; Myelodysplastic Syndromes | 1994 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blast Crisis; Blood Cell Count; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Gene Expression; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk; Salvage Therapy; Treatment Outcome | 1995 |
[Plasma concentration of cytosine arabinoside (Ara-C) in the elderly patients with hematological malignancy treated by Ara-C or cytarabine ocfosfate (SPAC)].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleotides; Cytarabine; Cytidine Monophosphate; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes | 1995 |
Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chromosome Inversion; Chromosome Mapping; Chromosomes, Human, Pair 16; Cytarabine; Cytogenetics; Humans; Karyotyping; Leukemia, Myeloid; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Sequence Deletion; Survival Rate; Treatment Outcome | 1995 |
[Differentiation therapy for myelodysplastic syndrome].
Topics: Adult; Aged; Aged, 80 and over; Cell Differentiation; Cytarabine; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Podophyllotoxin | 1993 |
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.
Topics: Adult; Aged; CD4 Antigens; Cytarabine; Dose-Response Relationship, Drug; Female; Hemoglobins; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Thymopentin | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Leukemia; Lung Diseases, Interstitial; Male; Methylprednisolone; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Tissue Donors; Treatment Outcome; Whole-Body Irradiation; Wisconsin | 1995 |
Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Hematopoiesis; Humans; Methotrexate; Methylation; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Restriction Fragment Length; Remission Induction | 1994 |
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Tissue Donors | 1994 |
Low-dose ARA-C consistently induces hematologic responses in the clinical 5q- syndrome.
Topics: Aged; Biopsy; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Treatment Outcome | 1994 |
[Allogeneic bone marrow transplantation for two patients with acute myeloid leukemia with trilineage myelodysplasia (T-MDS)].
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Graft vs Host Disease; Humans; Leukemia, Myelomonocytic, Acute; Male; Myelodysplastic Syndromes | 1994 |
Disseminated Mycobacterium avium-intracellulare infection in a patient with myelodysplastic syndrome (refractory anemia).
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Refractory; Bone Marrow; CD4 Antigens; Cytarabine; Dose-Response Relationship, Drug; Female; Gastric Juice; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophage Colony-Stimulating Factor; Mycobacterium avium-intracellulare Infection; Myelodysplastic Syndromes; Recombinant Proteins; T-Lymphocytes; Time Factors | 1994 |
Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model.
Topics: Acute Disease; Aged; Aged, 80 and over; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Survival Rate | 1994 |
der(Y)t(Y;1) is a nonrandom abnormality in myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 8; Cytarabine; Doxorubicin; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Translocation, Genetic; Trisomy; Y Chromosome | 1993 |
[Treatment of myelodysplastic syndrome by combined traditional Chinese medicine and Western medicine therapy].
Topics: Adolescent; Adult; Aged; Cell Transformation, Neoplastic; Cytarabine; Drugs, Chinese Herbal; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyridoxine; Stanozolol; Tretinoin | 1993 |
[Granulocyte function in myelodysplastic syndrome before and after low-dose cytarabine therapy].
Topics: Aged; Aged, 80 and over; Cytarabine; Drug Administration Schedule; Female; Granulocytes; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Phagocytosis; Regression Analysis; Skin Window Technique | 1993 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Megakaryocytic ploidy in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Azure Stains; Biomarkers; Cytarabine; DNA; Female; Flow Cytometry; Humans; Indoles; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Ploidies; Polyploidy; Remission Induction | 1993 |
[Successful treatment with combination chemotherapy of BHAC-AMP in a case of acute myelofibrosis developed from myelodysplastic syndrome with multiple chromosomal aberrations].
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Cytarabine; Humans; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Primary Myelofibrosis | 1993 |
Idarubicin in combination with cytarabine and VP-16 in the treatment of post myelodysplastic syndrome acute myeloblastic leukemia (MDS-AML).
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1995 |
Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cell Line, Transformed; Cells, Cultured; Child; Child, Preschool; Chromosomes, Human, Pair 21; Cystathionine beta-Synthase; Cytarabine; Deoxycytosine Nucleotides; Disease-Free Survival; Down Syndrome; Female; Herpesvirus 4, Human; Homocysteine; Humans; Infant; Infant, Newborn; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Male; Methotrexate; Myelodysplastic Syndromes; Neoplastic Stem Cells; Remission, Spontaneous; Survival Rate | 1996 |
A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate content in human materials in vivo.
Topics: Alkaline Phosphatase; Arabinofuranosylcytosine Triphosphate; Blast Crisis; Cell Line; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Radioimmunoassay; Sensitivity and Specificity; Tumor Cells, Cultured | 1996 |
High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methylprednisolone; Mitoxantrone; Myelodysplastic Syndromes | 1995 |
A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Remission Induction; Risk Factors | 1996 |
Myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry.
Topics: Antigens, CD; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Division; Cytarabine; Erythropoiesis; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cells; Humans; Immunophenotyping; Leukocytes; Myelodysplastic Syndromes; Reference Values | 1995 |
[Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leu
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blast Crisis; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Myelodysplastic Syndromes; Phosphorylation; Tyrosine | 1996 |
Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Platelet Transfusion; Thioguanine; Thrombocytopenia | 1997 |
Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Follow-Up Studies; Graft Survival; Humans; Infant; Leukemia; Myelodysplastic Syndromes; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 1997 |
Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Fanconi Anemia; Female; Humans; Karyotyping; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 1997 |
Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Time Factors; Treatment Outcome | 1996 |
FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Vidarabine | 1997 |
Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Cytarabine; Deamination; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1997 |
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Length of Stay; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Platelet Count; Survival Rate; Treatment Outcome; Vidarabine | 1997 |
[Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; DNA; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Retrospective Studies; Vincristine | 1998 |
[Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Myeloid; Life Tables; Male; Myelodysplastic Syndromes; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Thioguanine; Treatment Outcome; Vincristine; Waldenstrom Macroglobulinemia | 1998 |
Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome.
Topics: Aclarubicin; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biopsy; Cytarabine; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Male; Myelodysplastic Syndromes; Prednisolone; Pyoderma Gangrenosum; Recurrence; Skin | 1998 |
Aspects on the clinical use of hematopoietic growth factors in myelodysplastic syndromes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Daunorubicin; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Myelodysplastic Syndromes; Remission Induction; Thioguanine | 1998 |
A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological re
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Disease Progression; Hematopoiesis, Extramedullary; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Prednisolone; Preleukemia; Remission Induction | 1998 |
[Cytarabine-induced pericarditis].
Topics: Aged; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pericarditis | 1998 |
Pseudomonas aeruginosa orbital phlegmon in a patient treated for myelodysplastic syndrome with concomitant Sjögren's syndrome.
Topics: Aged; Anemia; Cytarabine; Eye Infections; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukopenia; Myelodysplastic Syndromes; Orbital Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Sjogren's Syndrome; Tomography, X-Ray Computed | 1999 |
Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient.
Topics: Acute Disease; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; Etoposide; Female; Humans; Idarubicin; Imipenem; Kidney Transplantation; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Thienamycins | 1999 |
In vitro development of haemopoietic progenitors in myelodysplastic syndromes (MDS)
Topics: Antigens, CD34; Antimetabolites, Antineoplastic; CD36 Antigens; Cytarabine; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes | 1999 |
Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome.
Topics: Acute Kidney Injury; Antimetabolites, Antineoplastic; Cytarabine; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Liver Failure; Middle Aged; Myelodysplastic Syndromes | 1999 |
Low-dose cytarabine (LD-AraC) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for myelodysplastic syndromes (MDS)
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 8; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Outcome; Trisomy | 1999 |
De novo acute myelogenous leukemia with trilineage myelodysplasia associated with t(8;21)(q22;q22).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Translocation, Genetic | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34.
Topics: Antibodies; Antigens, CD34; Cell Count; Cytarabine; Dactinomycin; Flow Cytometry; Fluorescent Dyes; Humans; Leukemia, Myeloid, Acute; Leukocyte Common Antigens; Light; Myelodysplastic Syndromes; Scattering, Radiation; Sensitivity and Specificity; Stem Cells; Tumor Cells, Cultured | 1999 |
[An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Myelodysplastic Syndromes | 2000 |
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2000 |
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Myelodysplastic Syndromes; Tumor Cells, Cultured | 2000 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Infections; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Sweden; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Japan; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate | 2000 |
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Dosage Compensation, Genetic; Female; Follow-Up Studies; Hematopoiesis; Humans; Idarubicin; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Retrospective Studies; Thioguanine; Time Factors | 2000 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Mapping; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 9; Cytarabine; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Isoenzymes; Karyotyping; Leukemia, Myelomonocytic, Acute; Metaphase; Middle Aged; Myelodysplastic Syndromes; Poly-ADP-Ribose Binding Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Thioguanine | 2001 |
Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Cytarabine; Female; Fetal Blood; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2001 |
Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations.
Topics: Adenosine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Cells; Carrier Proteins; Cell Survival; Cytarabine; Flow Cytometry; Fluorescent Dyes; Humans; Ligands; Membrane Proteins; Methotrexate; Myelodysplastic Syndromes; Nucleoside Transport Proteins; Thionucleosides | 2001 |
Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Topics: Acute Disease; Age Factors; Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholinesterases; Cytarabine; Daunorubicin; Disease Progression; Female; Humans; Japan; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Remission Induction; Risk Factors; Survival Analysis; Survival Rate | 2002 |
ABEP as primary chemotherapy for Hodgkin's disease.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine | 1992 |
A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia.
Topics: Aged; Aged, 80 and over; Anemia, Sideroblastic; Bone Marrow; Chromosome Aberrations; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Platelet Count; Predictive Value of Tests | 1992 |
Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
Topics: Aged; Aged, 80 and over; Calcitriol; Cytarabine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Tretinoin | 1992 |
Primary myelodysplastic syndrome: an analysis of 56 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cause of Death; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate | 1992 |
Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
Topics: Aged; Bone Marrow Examination; Cytarabine; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Treatment Failure | 1992 |
Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous | 1992 |
[Cytosine arabinoside in low doses in the treatment of myelodysplastic syndrome. Czechoslovak MDS Cooperative Group].
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1992 |
Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
Topics: Acute Disease; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes | 1992 |
Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Bone Marrow; Bone Marrow Cells; Bone Marrow Transplantation; CD5 Antigens; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Graft vs Host Disease; Humans; Immunotoxins; Leukemia; Middle Aged; Myelodysplastic Syndromes; Ricin; Risk Factors; T-Lymphocytes; Whole-Body Irradiation | 1990 |
Myelodysplastic syndromes: analysis of 51 cases. Therapy with low doses of arabinosyl cytosine of leukaemic transformation.
Topics: Aged; Cytarabine; Cytogenetics; Humans; Leukemia; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis | 1990 |
Therapy of myelodysplastic syndromes: advances and perspectives. Innsbruck, Austria, October 7-10, 1990.
Topics: Bone Marrow Transplantation; Clinical Trials as Topic; Cytarabine; Erythropoiesis; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Interleukin-1; Interleukin-6; Myelodysplastic Syndromes | 1991 |
Low dose cytosine arabinoside in the treatment of the primary myelodysplastic syndrome.
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1990 |
The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study.
Topics: Cytarabine; Dose-Response Relationship, Drug; Granulocytes; Hematopoiesis; Hematopoietic Stem Cells; Humans; Macrophages; Myelodysplastic Syndromes; T-Lymphocyte Subsets; T-Lymphocytes; T-Lymphocytes, Regulatory | 1991 |
Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity.
Topics: Acute Disease; Aged; Aged, 80 and over; Cell Division; Cell Survival; Cytarabine; Female; Granulocytes; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes | 1991 |
[Myelodysplasia predominantly involving in megakaryocytic lineage successfully treated with low-dose Ara-C].
Topics: Adolescent; Cytarabine; Drug Administration Schedule; Humans; Leukemia, Megakaryoblastic, Acute; Male; Myelodysplastic Syndromes; Primary Myelofibrosis | 1991 |
Cytogenetic and clonal culture evaluation after response to low dose Ara-C in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Bone Marrow; Cells, Cultured; Chromosome Aberrations; Cytarabine; Female; Hematopoiesis; Hematopoietic Stem Cells; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1991 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors | 1991 |
[Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Rate | 1991 |
Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cerebellar Diseases; Cyclosporins; Cytarabine; Diarrhea; Evaluation Studies as Topic; Female; Georgia; Humans; Leukemia; Lymphoma; Male; Methotrexate; Myelodysplastic Syndromes; Preoperative Care; Remission Induction; Retinitis; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1990 |
[Myelodysplastic syndrome (RAEB-T) occurring after adjuvant chemotherapy for colon and rectum cancers].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colonic Neoplasms; Cytarabine; DNA Damage; DNA, Neoplasm; Humans; Male; Mitomycin; Mitomycins; Myelodysplastic Syndromes; Rectal Neoplasms; Tegafur | 1990 |
Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Cell Differentiation; Cell Division; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Drug Evaluation; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Hematopoiesis; Humans; Leukocyte Count; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Recombinant Proteins | 1990 |
Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome.
Topics: Aged; Colony-Stimulating Factors; Cytarabine; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Indium Radioisotopes; Leukemia; Lymphocyte Activation; Myelodysplastic Syndromes; Splenomegaly | 1990 |
Cytosine arabinoside does not cause differentiation in vitro of CFU-GM in marrow from normal, myelodysplastic or ANLL subjects.
Topics: Alkaline Phosphatase; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cytarabine; Granulocytes; Histocytochemistry; HLA-DR Antigens; Humans; Immunohistochemistry; In Vitro Techniques; Leukemia, Myeloid, Acute; Macrophages; Myelodysplastic Syndromes; Stem Cells | 1990 |
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
Topics: Acute Disease; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Time Factors | 1990 |
Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Preleukemia; Remission Induction; Thioguanine | 1990 |
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients.
Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Cytarabine; Daunorubicin; Female; Hemoglobins; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Platelet Count; Prognosis; Remission Induction; Survival Rate | 1990 |
[Treatment of myelodysplastic syndrome using continual subcutaneous infusion of low doses of cytosine arabinoside].
Topics: Aged; Aged, 80 and over; Cytarabine; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Myelodysplastic Syndromes | 1990 |
Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
Topics: Adult; Age Factors; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Retrospective Studies | 1990 |
Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Blast Crisis; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Female; Histocytochemistry; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
[Recent progress in the treatment of hematological malignancies. III. Management of patients with myelodysplastic syndromes and atypical leukemias].
Topics: Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interferon-gamma; Myelodysplastic Syndromes | 1989 |
Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.
Topics: Adult; Aged; Cell Separation; Clone Cells; Cytarabine; DNA Mutational Analysis; Female; Genes, ras; Genetic Linkage; Genetic Markers; Hematopoietic Stem Cells; Humans; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Restriction Fragment Length; X Chromosome | 1989 |
ras gene mutations and clonal analysis using RFLPs of X-chromosome genes in myelodysplastic syndromes.
Topics: Blotting, Southern; Cloning, Molecular; Cytarabine; Genes, ras; Humans; Mutation; Myelodysplastic Syndromes; Polymorphism, Restriction Fragment Length; X Chromosome | 1989 |
[Study on pathophysiology of the myelodysplastic syndromes (MDS)--pattern of dysmegakaryopoiesis related to leukemic transformation].
Topics: Aged; Cytarabine; Female; Hematopoiesis; Humans; Leukemia; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes | 1989 |
Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Retrospective Studies | 1989 |
Effects of retinoic acid, 1,25-dihydroxyvitamin D3, cytosine arabinoside and alpha-interferon on bone marrow cells from patients with myelodysplastic syndromes.
Topics: Bone Marrow; Calcitriol; Cell Differentiation; Cell Division; Colony-Forming Units Assay; Cytarabine; DNA; Humans; In Vitro Techniques; Interferon Type I; Myelodysplastic Syndromes; Tretinoin | 1989 |
Limitations of the therapeutic regimens for myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Humans; Hydroxyurea; Male; Middle Aged; Myelodysplastic Syndromes | 1989 |
[Ventricular fibrillation in a patient with myelodysplastic syndrome treated with small doses of cytarabine].
Topics: Cytarabine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Ventricular Fibrillation | 1989 |
Evaluation of low-dose cytarabine therapy in myelodysplastic syndromes.
Topics: Aged; Cytarabine; Drug Evaluation; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1989 |
Therapy of advanced myelodysplastic syndrome with aggressive chemotherapy.
Topics: Adult; Aged; Bone Marrow Transplantation; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1989 |
Bone marrow transplantation for children with myelodysplastic syndromes.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Male; Myelodysplastic Syndromes | 1989 |
Double autologous bone marrow transplantation in acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Evaluation Studies as Topic; Female; Humans; Leukemia, Myeloid, Acute; Male; Methods; Middle Aged; Myelodysplastic Syndromes; Thioguanine; Transplantation, Autologous | 1989 |
Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine arabinoside in patients with myelodysplastic syndrome. A pilot study.
Topics: Adult; Aged; Blast Crisis; Bone Marrow; Colony-Stimulating Factors; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukocyte Count; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins | 1989 |
[Relation of karyotypic findings to chemotherapy response in patients with preleukemia].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Preleukemia | 1989 |
[Marked dysmyelopoiesis after induction chemotherapy in a case of acute myelomonocytic leukemia (M 4) with t(6; 11)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 6; Cytarabine; Daunorubicin; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Acute; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Translocation, Genetic | 1989 |
Low-dose cytosine arabinoside in myelodysplastic syndromes.
Topics: Aged; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 1989 |
The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Thioguanine | 1989 |
Response of a case of myelodysplastic syndrome with partial myeloperoxidase deficiency to continuous infusion of low-dose cytosine arabinoside.
Topics: Adult; Cytarabine; Humans; Male; Myelodysplastic Syndromes; Peroxidase; Remission Induction | 1987 |
Treatment of MDS with special reference to the effects of androgen on ineffective erythropoiesis.
Topics: Aged; Androgens; Cholecalciferol; Cytarabine; Drug Therapy, Combination; Erythropoiesis; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1988 |
Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly.
Topics: Aged; Cytarabine; Female; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
Treatment for myelodysplastic syndromes.
Topics: Aged; Calcitriol; Cytarabine; Drug Synergism; Drug Therapy, Combination; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Retinoids | 1987 |
Treatment for myelodysplastic syndromes.
Topics: Cytarabine; Drug Therapy, Combination; Humans; Isotretinoin; Myelodysplastic Syndromes; Tretinoin | 1987 |
Phase I/II study with GM-CSF in patients with myelodysplastic syndromes.
Topics: Colony-Stimulating Factors; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Leukocyte Count; Myelodysplastic Syndromes; Recombinant Proteins | 1988 |
Low-dose cytarabine in myelodysplastic syndromes and acute leukemia. A comment.
Topics: Acute Disease; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia; Myelodysplastic Syndromes | 1986 |
[Effect of low-dose Ara-C regimen on myelodysplastic syndrome (MDS)].
Topics: Aged; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1988 |
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine.
Topics: Adult; Aged; Biopsy, Needle; Bone Marrow; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1988 |
Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes.
Topics: Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis | 1988 |
Results of aggressive chemotherapy for myelodysplastic syndromes.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine | 1988 |
Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy.
Topics: Cytarabine; Female; Genes, ras; Humans; Middle Aged; Mutation; Myelodysplastic Syndromes | 1988 |
Low dose Ara-C for patients with myelodysplastic syndromes.
Topics: Adult; Aged; Bacterial Infections; Blood Cell Count; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1988 |
Effectiveness of attenuated chemotherapy in myelodysplastic syndromes: a preliminary report.
Topics: Aged; Blood Cell Count; Bone Marrow; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine | 1988 |
[Experiences with low-dos Ara-C in the therapy of hematological neoplasms].
Topics: Adult; Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1988 |
[Treatment of patients with myelodysplastic syndrome using low doses of cytosar].
Topics: Blood Transfusion; Combined Modality Therapy; Cytarabine; Female; Humans; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1988 |
Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Hydroxycholecalciferols; Interferon Type I; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Tretinoin | 1988 |
[Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Nausea | 1988 |
[Intensive chemotherapy of refractory anemia with excess of blasts].
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Infusions, Intravenous; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Remission Induction; Vincristine | 1988 |
[A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].
Topics: Acute Disease; Adult; Aged; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1988 |
[Effectiveness of low dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes--analysis of factors influencing the duration of responses, survival and clinical effects].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction | 1987 |
Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromosome Aberrations; Cytarabine; Female; Germany, West; Humans; Infant; Italy; Male; Myelodysplastic Syndromes | 1987 |
[Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
Topics: Aged; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
[Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
Topics: Adolescent; Adult; Aged; Child; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Parenteral; Injections, Subcutaneous; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
[Retrospective study of 30 cases of myelodysplastic syndrome according to the French-American-British classification].
Topics: Aged; Anemia, Refractory; Anemia, Sideroblastic; Bone Marrow; Cytarabine; Female; Hematopoietic Stem Cells; Humans; International Cooperation; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Retrospective Studies | 1987 |
[Acute myeloblastic leukemias and myelodysplasias: treatment with low doses of aracytine].
Topics: Aged; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes | 1986 |
Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow; Cytarabine; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Time Factors | 1987 |
[Round table: Differentiation of human malignant lymphoid and myeloid cells].
Topics: Cell Differentiation; Cell Line; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplastic Stem Cells | 1987 |
Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction; Time Factors | 1987 |
[Cytarabine].
Topics: Animals; Antineoplastic Agents; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Structure-Activity Relationship | 1987 |
Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A.
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Naphthacenes | 1987 |
Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Differentiation; Cytarabine; Drug Synergism; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Thioguanine; Tretinoin; Tumor Cells, Cultured; Vincristine | 1987 |
The effect of low dose ARA-C on in-vitro haemopoiesis of marrow cells from myelodysplastic patients.
Topics: Bone Marrow; Cell Differentiation; Cell Division; Cell Survival; Colony-Forming Units Assay; Cytarabine; Hematopoiesis; Humans; In Vitro Techniques; Myelodysplastic Syndromes; Phagocytosis | 1987 |
[The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
Topics: Acute Disease; Adult; Aged; Chromatography, High Pressure Liquid; Cytarabine; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1987 |
In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
Topics: Acute Disease; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Transformation, Neoplastic; Cells, Cultured; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia; Middle Aged; Myelodysplastic Syndromes | 1987 |
The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.
Topics: Bone Marrow Cells; Cell Division; Colony-Forming Units Assay; Cytarabine; Granulocytes; Humans; Macrophages; Myelodysplastic Syndromes | 1987 |
Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.
Topics: Acute Disease; Cytarabine; Humans; Leukemia; Myelodysplastic Syndromes; Prognosis | 1987 |
[A phase II study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. Cooperative Study Group for PL-AC].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytarabine; Drug Evaluation; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1987 |
Low-dose Ara-C in myelodysplastic syndromes and acute nonlymphoid leukemia. Experience with seven patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes | 1987 |
Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders | 1986 |
The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes.
Topics: Adolescent; Adult; Age Factors; Aged; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Time Factors | 1986 |
Low-dose cytosine arabinoside in myelodysplastic syndromes.
Topics: Aged; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 1986 |
[Myelodysplastic syndromes].
Topics: Chromosome Aberrations; Cytarabine; Humans; Leukemia; Myelodysplastic Syndromes; Prognosis | 1986 |
[Treatment of myelodysplastic syndrome (MDS)].
Topics: Adult; Aged; Antineoplastic Agents; Blood Transfusion; Cyclophosphamide; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 1986 |
[Clinical effect of low-dose Ara-c and its mechanism of antileukemic action].
Topics: Bone Marrow; Cytarabine; Drug Administration Schedule; Humans; Myelodysplastic Syndromes; Remission Induction | 1986 |
Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine.
Topics: Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 1985 |
[Myelodysplastic syndromes].
Topics: Acute Disease; Androgens; Cytarabine; Glucocorticoids; Hemorrhage; Humans; Immunotherapy; Infections; Leukemia; Myelodysplastic Syndromes; Prognosis; Vitamins | 1985 |
Treatment of dysmyelopoietic/leukemic syndromes with myelofibrosis and megakaryocytic hyperplasia with large doses of cytosine arabinoside.
Topics: Acute Disease; Adult; Aged; Biopsy; Blood Cell Count; Bone Marrow; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Hyperplasia; Leukemia; Male; Megakaryocytes; Middle Aged; Myelodysplastic Syndromes; Pancytopenia; Primary Myelofibrosis; Thrombocythemia, Essential | 1985 |